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ABSTRACT
Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the gene encoding Cystic
Fibrosis Transmembrane Conductance Regulator (CFTR). This disorder results in thick lung
secretions which compromise the patient’s immune system. Chronic lung infections with
Pseudomonas aeruginosa biofilms is a major factor that contributes to poor outcome for clinical
treatment. The overall hypothesis of this dissertation is that small colony variant and pyrimidine
biosynthesis are linked with biofilm formation, alginate production is dependent on MucA
proteolysis, rifaximin can be repurposed to treat biofilm infection and multiplex PCR can be
used to rapidly measure the bacterial cell density in patients’ respiratory secretions. Using
transposon mutants in the de novo pyrimidine biosynthesis, it was established that two sigma
factors AlgU (σ22) and RpoN (σ54) compete for alginate biosynthesis promoter binding. The
balance of intracellular sigma factors created a competition that drove the bacteria to switch
between small colony variance (SCV), under pyrimidine starvation, and alginate overproduction,
under normal cellular conditions. We showed that the addition of uracil to the growth media is
able to recover the normal mucoid phenotype in the pyrimidine mutants. Furthermore, it was
shown that proteolysis of MucA22, a truncated MucA mutant, is necessary for the initiation of
the signal transduction to release AlgU resulting in alginate production. Rifaximin was shown to
be a potential anti-biofilm adjuvant, to the current treatment for CF lung infections, tobramycin.
Finally, we developed a multiplex PCR that may be used for rapid diagnosis of lower respiratory
tract infections such as CF lung infection and/or ventilator associated pneumonia. In conclusion,
this dissertation studied the transcriptional and post-translational regulation of alginate
production in P. aeruginosa as well as establishing a previously unknown link between alginate
production and pyrimidine de novo biosynthesis. This knowledge would aid in identifying

xiii

potential targets for future therapeutics. Also, we optimized current treatments of CF lung
infections by repurposing a current antibiotic as an adjuvant, as well as developed a possible
rapid diagnostic tool. Our work aims to help reduce mortality of CF patients from chronic
infections by mucoid P. aeruginosa and improve the patients’ quality of life.
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Abstract
Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that causes
several infections, notably a chronic lung infection in patients that suffer from Cystic Fibrosis.
The ability of P. aeruginosa to adapt to the harsh lung environment allows it to persist in the
lung and transition from the initial virulent acute infection to a mucoid chronic infection. In this
review we will discuss the ability of P. aeruginosa to infect CF patients and adapt to the lungs.
Moreover, we will discuss the process of regulation and biosynthesis of the exopolysaccharide
alginate that is critical for immune evasion and protection of the bacteria in the lungs.
Introduction
Chronic lung infections by Pseudomonas aeruginosa in patients with Cystic Fibrosis
(CF) is the main cause for morbidity and mortality (Bhagirath et al., 2016). Pseudomonas
aeruginosa enters the airways of CF patients and adapts to the favorable conditions in the lung
that results in a chronic infection. The main factor in the chronic lung infection is the ability of
the Pseudomonas aeruginosa to produce the exopolysaccharide alginate.
This review will cover the different aspects of the persistent lung infection in CF patients
caused by P. aeruginosa. We will identify the acute phase of infection by Pseudomonas and its
ability to adapt to the CF lung and become the dominant species causing chronic illness. Finally,
we will explain the regulation process by which P. aeruginosa produces the exopolysaccharide
alginate through the proteolysis of the main anti-sigma factor MucA.
Cystic Fibrosis
Cystic Fibrosis, also known as mucoviscidosis (Kargul & Irminger-Finger, 2014) is an
autosomal recessive genetic illness that has an incidence of 1 in 2500 to 4000 in Caucasians
(Davies, Ebdon, & Orchard, 2014). The illness is the result of a mutation in the Cystic Fibrosis
2

Transmembrane Conductance Regulator (CFTR) with the deletion of phenylalanine at position
508 (F508del) being the most common mutation seen in patients (Cohen & Prince, 2012; Lewis
et al., 2005). The CFTR is found in the lungs, pancreas, heart, and the digestive tract; therefore,
mutations in the channel results in disruption in the secretions in all these systems (Crawford et
al., 1991). The CFTR channel has a main role in chloride ion transport (Cl-); in addition it plays a
role in sodium (Na+) and bicarbonate (HCO3-) transport (Cohen & Prince, 2012). In the lower
respiratory tract submucosal glands produce the required mucus (Bhagirath et al., 2016). The
mucocilliary system in the lungs is comprised of the ciliated epithelial cells and mucus, and is
separated by a layer of airway surface liquid (J. Rao et al., 2011; Bhagirath et al., 2016). This
mucus traps inhaled bacteria. Defects in the mucocilliary transport result in recurring lung
infections in CF patients (Gomez & Prince, 2007; Ratjen, 2009). The disruption of function
results in pumping of chloride into the extracellular space that causes thickening, dehydration
and increase in viscosity of mucus (Bhagirath et al., 2016; Doring, Flume, Heijerman, & Elborn,
2012). In CF patients, the CFTR mutation results in the thinning of ASL due to dehydration
resulting in mucins being brought closer to ciliated epithelial cells and attaching, thereby
inhibiting the beating and allows the formation of mucus plaques (Bhagirath et al., 2016; Burgel,
Montani, Danel, Dusser, & Nadel, 2007; Martens et al., 2011). The mucus plaques result in
pockets of anaerobic or microaerobic regions within the airways (Kreda, Davis, & Rose, 2012;
Worlitzsch et al., 2002). This mucus also results in acidification of the airway environment
which further inhibits the body’s immune defense mechanisms and decreases the effect of
antimicrobials (Pezzulo et al., 2012; Shah et al., 2016). All these conditions make it favorable for
bacteria, that would otherwise be cleared in a normal person, to cause persistent infections in CF
patients.
3

Pseudomonas aeruginosa and Lung Infection
Pseudomonas aeruginosa is usually acquired early in the CF patient’s life commonly
from the hospital setting, since they spend a large amount of time in hospitals which increases
their risk of exposure to it. Once acquired the infection starts as an acute infection that is very
different from the infection that persists (Sousa & Pereira, 2014). Various factors contribute into
converting the initial infective strain into the chronic phenotype.
Early in the acquisition phase P. aeruginosa is still very virulent, expressing several
virulence factors that would aid its propagation through the lung. The first factor is the type III
secretion system (T3SS); this is used by the bacteria for translocating effectors from the bacterial
cell (Hauser, 2009). The T3SS is necessary for the acute invasion and the dissemination of
bacteria through the lungs (Rangel, Diaz, Knoten, Zhang, & Hauser, 2015; Shaver & Hauser,
2004; Wiener-Kronish et al., 1993). The second factor is motility. In the acute phase of the
infection P. aeruginosa still has its polar flagellum that it uses for motility as well as for
flagellar-host immune system interaction (Faure, Kwong, & Nguyen, 2018). P. aeruginosa has a
large array of secreted proteases that are used for acute virulence such as pyoverdine,
phospholipase C, and hemolysin (Sousa & Pereira, 2014). During the acute phase of the infection
strains are normally non-mucoid and still have a functional quorum sensing (QS) circuit that aids
in cell to cell communication (Abdel-Mawgoud, Lepine, & Deziel, 2010; Burns et al., 2001;
Manos et al., 2013; Pacheco et al., 2012). Moreover, strains are usually more sensitive to
antimicrobials as compared to the chronic variants, and they have a lower frequency of mutations
(Y. H. Li & Tian, 2012; Montanari et al., 2007).
Once an infection is established in the airways of CF patient, the strains switch
phenotypes and genotypes from being the virulent, invasive acute strain to the biofilm producing
4

chronic form. Several factors contribute to the conversion to chronic infection that include the
oxidative stress in the lung, nutrient deficiency, antimicrobial treatments, competition with other
infection causing bacteria in the lung, and the patient’s immune system (Bhagirath et al., 2016).
These factors result in a highly selective pressure that drives P. aeruginosa to adapt to the CF
lung through mutations or various phenotyping, genotypic, or metabolic switching (Folkesson et
al., 2012; Furukawa, Kuchma, & O'Toole, 2006). The main factor associated with chronic
infections of P. aeruginosa is the ability of the strain to produce the exopolysaccharide alginate.
The mucoidy phenotype -alginate overproducing strain- is linked to poor prognosis (Hogardt &
Heesemann, 2010). Several factors contribute to the conversion of a non-mucoid strain into the
mucoid strain, including the stress conditions in the CF lung that select for mucoidy mutants
since alginate is protective (Bragonzi et al., 2005; Mathee et al., 1999). Mucoidy can be a result
of spontaneous mutations in the anti-sigma factor, MucA, that regulates the sigma factor
associated with alginate production, AlgU (σ22) (Wood & Ohman, 2012); this will be discussed
further later in this review. Chronic infections are characterized by the loss of motility due to the
loss of the polar flagellum; this aids the cell in immune evasion and helps decrease rate of
phagocytosis by the alveolar macrophages (Chang, Klockgether, & Tummler, 2007; Lightfield et
al., 2011). In addition to loss of motility, several other acute virulence factors are shut down in
the chronic strains such as T3SS (Hogardt, Roeder, Schreff, Eberl, & Heesemann, 2004), the
LasR pathway of QS (Arora, Ritchings, Almira, Lory, & Ramphal, 1997; Winstanley, O'Brien,
& Brockhurst, 2016; Yang et al., 2017), and exotoxin production like siderophores, pyocins and
elastase (Hogardt et al., 2007; van der Plas et al., 2016). During the chronic infection the
Pseudomonas LPS is modified, resulting in the loss of the lipid A structure that helps in immune
evasion (Ernst et al., 2006; Moskowitz & Ernst, 2010; Needham & Trent, 2013). The switch
5

from acute infection to chronic infection can be also attributed to the Gac-RsmA pathway
(Goodman et al., 2004; Kong et al., 2013; Kuang et al., 2011; Ventre et al., 2006), where RetS
(sensor kinase) represses the GacAS (two-component system) pathway and thereby upregulating
virulence factors such as T3SS and downregulating biofilm formation. On the other hand, during
chronic infections the GacAS pathway is induced thereby lowering the expression of virulence
pathways and leading to biofilm production (Goodman et al., 2004).
Another phenotype that is linked to chronic infections is the small colony variant (SCV).
These strains produce colonies that are smaller than normal colonies on growth plates and are a
result of the stressful CF lung environment that includes nutrient starvation (Haussler, Tummler,
Weissbrodt, Rohde, & Steinmetz, 1999). SCV are more resistant to antimicrobials (Haussler et
al., 1999), hyperpilliated, more adherent and have a higher expression of the pel and psl biofilm
polysaccharides (Haussler et al., 2003; Kirisits, Prost, Starkey, & Parsek, 2005; Lory, Merighi, &
Hyodo, 2009; Starkey et al., 2009).
Some of the metabolic changes that a chronic strain goes through deal with alteration of
nutrient source (Behrends et al., 2013) or the fact that the strain might be in an anaerobic or
microaerobic part of the lung as opposed to the aerobic environment the acute infection was in.
To adapt to the lower oxygen availability Pseudomonas can use NO3 -/NO2 - as an electron
acceptor (Worlitzsch et al., 2002) regulated by the anaerobic regulators (ANR). Moreover
several marker genes are upregulated under the anaerobic/hypoxic conditions in order to help the
cell adapt to the lower oxygen levels (Eichner et al., 2014). The nutrient constraints that arise in
the CF lung (Bhagirath et al., 2016) force the P. aeruginosa colonies to adapt to be able to
continue to have a carbon source. Pseudomonas in chronic infections become auxotrophic for
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amino acids mainly Methionine since the CF lung is abundant with amino acids (Barth & Pitt,
1996; Thomas, Ray, Hodson, & Pitt, 2000).
The harsh CF environment puts a selective pressure on the chronic bacteria in the lung
and aids in propagating spontaneous mutations that would aid in survival. The early mutations
are a result of the treatment regimens of antibiotics that produce a selective pressure for adaptive
resistance (Bhagirath et al., 2016). Other adaptive mutations are in the mucA gene, as mentioned
earlier, where this selects for mucoid bacteria since alginate is used for protection from both the
host immune system as well as the antimicrobials used for treatment. This selective pressure
drives the bacteria to become hypermutators (Casilag et al., 2016; Lo et al., 2016), resulting in a
heterogenous population in the lungs (Bhagirath et al., 2016).
Though Pseudomonas aeruginosa is the dominant species in the CF lung, several other
pathogens infect the CF lung and indeed develop into a chronic infection alongside
Pseudomonas (O'Brien & Fothergill, 2017) such as Acinetobacter baumannii, Burkholderia
cepacia, Staphylococcus aureus, and Haemophilus influenza (Baldan et al., 2014; Bhagirath et
al., 2016; Carmody et al., 2015). S. aureus and H. influenza are usually the most common
pathogens at an early age, where P. aeruginosa is the more dominant species later on in the
patient’s life (Coutinho, Falcao-Silva, & Goncalves, 2008; Marvig, Sommer, Molin, & Johansen,
2015; Williams et al., 2015). These various species co-exist in the CF lung and compete against
each other. Interestingly, the acute phase of P. aeruginosa infection is antagonistic with S.
aureus through the QS system. Yet in the chronic biofilm producing phase, P. aeruginosa is less
competitive and coinfections of both bacteria are more common (Limoli et al., 2017).

7

Alginate Production and Mucoidy
As mentioned above, alginate is the main marker in a chronic lung infection by P.
aeruginosa. Alginate is an exopolysaccharide that is produced from a polymer of β-1,4-linked
monomers of D-mannuronic acid and α-L-guluronic acid (C5 epimer of mannuronic acid)
(Linker & Jones, 1966). Below, we will discuss the regulated intramembrane proteolysis of the
cognate anti-sigma factor MucA for the sigma factor AlgU/T (σ22) that controls alginate
production in Pseudomonas aeruginosa (Govan & Deretic, 1996a).
The algU Operon
The first operon in alginate regulation and production pathway is the algUmucABCD
operon, and is involved in regulation of alginate (Mathee, McPherson, & Ohman, 1997). The
biosynthetic operon (algD operon) contains the necessary 12 genes encoding the enzymes and
proteins to produce alginate from fructose-6-phosphate, with algC being the only gene not
present on that operon (Ramsey & Wozniak, 2005).
The first gene involved in the algUmucABCD operon is the main sigma factor that
controls the alginate pathway; algU (algT/σ22). The second gene (mucA) encodes the cognate
anti-sigma factor MucA that sequesters AlgU and inhibits its function (Schurr, Yu, MartinezSalazar, Boucher, & Deretic, 1996). Mathee et al. showed that MucA has a single
transmembrane domain with the N-terminal domain being localized in the cytoplasm and the Cterminal domain being localized in the periplasm. MucA sequesters AlgU inside the cytoplasm at
its carboxyl-end. The proteolytic cleavage of MucA is under tight regulation and the cleavage of
MucA would result in the release of AlgU into the cytoplasm leading to the induction of the algU
promoter (PalgU) and algD promoter (PalgD) and hence alginate production (Schurr et al., 1996).
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The gene mucB (algN) produces a negative regulator of alginate in the form of MucB
(34.5 kDa, 316 Residues) (Mathee et al., 1997; Schurr et al., 1996). The inactivation of mucA,
mucB, or mucD results in the transcriptional activation of algD causing alginate production.
Moreover, insertional inactivation of mucB lead to high levels of σ 22 in the cell (Mathee et al.,
1997; Schurr et al., 1996). These results would lead to the conclusion that MucB has a protective
function for MucA (Cezairliyan & Sauer, 2009) thereby inhibiting its cleavage and the
subsequent release of σ22 (Mathee et al., 1997). MucB, when purified, was found in the
periplasmic fraction of the cell lysate; and the 21 amino acids at the N-terminal are likely used to
translocate the cytoplasmically-produced protein into the periplasmic space where it exerts its
negative affect on AlgU activity (Schurr et al., 1996). MucB was found to be generally
hydrophilic with the exception of the 21 amino acid signal sequence, that was hydrophobic
(Mathee et al., 1997). MucB binds to the C-terminal of MucA through protein-protein
interactions in the periplasm (Wood & Ohman, 2009). Moreover it was shown that MucB’s
binding to MucA is specific and reversible, and that MucB dimers bind to MucA, thereby
providing a scaffold for unstructured MucA to fully fold and protect it from AlgW proteolysis
(Cezairliyan & Sauer, 2009) .
The gene mucC (algM) a putative regulator gene, was first described by Boucher et al.
(Boucher et al., 1996). MucC, a homolog of ORF4 of Photobacterium and Azotobacter
vinelandii (Martinez-Salazar et al., 1996) has two potential transmembrane domains that results
in the possible MucC membrane association in order to either directly or indirectly affect
alginate production through stress signal transduction (Boucher et al., 1996). MucC is required
by Pseudomonas aeruginosa in order to grow under high temperature (42 °C) and high salt
concentration (300 mM NaCl) conditions. Moreover, MucC, under adverse growth conditions,
9

has a negative regulatory effect on alginate production where it functions synergistically with
both MucA and MucB inhibiting the release of AlgU into the cytoplasm (Boucher, Schurr, Yu,
Rowen, & Deretic, 1997). The complete function of mucC has not yet been fully described
(Wood & Ohman, 2006). What is known is that the promoter region of mucD is found 165 bases
upstream of mucD, in the mucC gene (Boucher, Schurr, et al., 1997) (Wood & Ohman, 2006).
The induction of this promoter alone resulted in half the amount of MucD produced, suggesting
that mucD is under both PalgU and PmucD control. The promoter PmucD is not regulated by any of
the known regulators of alginate production algU, mucA, mucB, mucD, algB, kinB, and rpoS
(Wood & Ohman, 2006).
The last gene in the algU mucABCD operon is mucD (algY) initially identified by
Boucher et al. MucD (53.9 kDa), a homolog of HtrA serine protease (DegP) in E. coli, has two
protein interaction motifs (PDZ domains) similar to DegP/HtrA (Boucher et al., 1996; Wood,
Leech, & Ohman, 2006) Inactivating mucD in PAO1 lead to the conversion of PAO1, a nonmucoid strain of P. aeruginosa, into a mucoid phenotype. The mucD mutant PAO1 also showed
increased susceptibility to H2O2 and elevated temperatures, where MucD is required for normal
growth under these conditions (Boucher et al., 1996). Based on the homolog (DegP) MucD was
likely hypothesized to be a periplasmic protease that degrades misfolded proteins that would
result from adverse conditions, such as high temperatures (Boucher et al., 1996; Wood et al.,
2006; Wood & Ohman, 2006). Qiu et al. showed that MucD removes misfolded proteins in the
periplasm, proteins that otherwise would activate the proteases that cleave MucA, releasing
AlgU, and resulting in a mucoidy phenotype (D. Qiu, Eisinger, Rowen, & Yu, 2007). Qiu et al.
also showed that the overexpression of mucD in a plasmid resulted in partial suppression of
mucoidy in PAO1VE2, a PAO1 strain that over-expresses mucE (D. Qiu et al., 2007).
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Regulated Intramembrane Proteolysis of MucA
The regulated intramembrane proteolysis (RIP) of MucA triggers the degradation of
MucA, the release of the sequestered σ22 sigma factor (AlgU/T), and thereby the induction of
alginate synthesis. In this section we will discuss the several proteases that degrade MucA,
including AlgW, MucP, and ClpXP/P2.
The first protease to cleave MucA to discuss is AlgW. AlgW is the homolog of DegS (a
periplasmic protease in E. coli) that cleaves RseA (Boucher et al., 1996). Insertional inactivation
of algW in PAO1(wild type nonmucoid reference P. aeruginosa strain) showed reduced viability
at high temperatures (50 °C), as well as significant susceptibility to H2O2, and paraquat, a
superoxide-generating redox cycling compound. This reduced viability suggested that AlgW has
a protective function in Pseudomonas (Wood et al., 2006). The amino-terminal of AlgW
functions as a membrane anchor and the carboxyl-terminal contains a single PDZ domain
(Cezairliyan & Sauer, 2009; D. Qiu et al., 2007; Wood et al., 2006). In order for AlgW to cleave
MucA efficiently, a second protein, MucE, is needed to activate AlgW (Cezairliyan & Sauer,
2009; D. Qiu et al., 2007). Mariner transposon insertion into mucE (PA4033) by Qiu et al. was
found to result in an overexpression of mucE causing a mucoid phenotype in PAO1, an otherwise
non-mucoid strain. At the C-terminal of MucE a three amino acid sequence of WVF was
required to activate AlgW to cleave MucA. Without the C-terminal of MucE, no mucoid
phenotype was seen in PAO1VE2- a PAO1 strain that over expresses mucE (D. Qiu et al., 2007).
Different variants of the terminal 3 amino acid sequence still allow for the activation of MucE; V
or I at the first position, W, Y and L at the second position and W or F at the third position have
similar ability to activate AlgW proteolysis. AlgW, through its PDZ domain, functions as a
sensor for a signal, such as the one produced by MucE or misfolded outer membrane proteins to
11

cleave MucA (Thompson, Webb, Rice, & Kjelleberg, 2003). On the other hand, the 16 amino
acid protein structure within AlgW, known as the LA Loop, controls its binding to MucA and
helps in regulating the proteolysis of MucA through inhibiting the protein-protein interactions
between AlgW and MucA (Cezairliyan & Sauer, 2009; D. Qiu et al., 2007). The LA loop of
AlgW, similar to that in its homolog DegS, influences the proteolytic activity. In LA loop
deficient AlgW the protease activity was similar to wt. AlgW in the absence of MucE with a K M
of the mutant was significantly lower. The lack of protease activity shows that the LA Loop of
AlgW controls all the protein interactions of AlgW with MucA thereby controlling the
proteolytic activity of AlgW and aiding in substrate discrimination (Cezairliyan & Sauer, 2009).
The second putative protease that cleaves MucA is MucP (PA3649), a homolog of
RseP/YaeL in E. coli. (Alba, Leeds, Onufryk, Lu, & Gross, 2002; D. Qiu et al., 2007). MucP has
a protease active site in the form of a highly conserved catalytic domain of zinc metalloprotease
(Damron & Yu, 2011). The inactivation of mucP led to a loss of mucoidy in the mucoid strain
PAO1VE2. Moreover, in PAO1 overexpressing MucE through a vector, the inactivation of mucP
lead to loss of mucoidy and a higher level of MucA and a lower level of AlgU when compared to
PAO1VE2. These results proved that MucE-induced mucoidy requires the activity of MucP (D.
Qiu et al., 2007). Exposure to D-cycloserine, a cell wall stress inducer, resulted in the complete
degradation of MucA in PAO1, but in PAO1algW MucA was not degraded. In PAO1mucP
exposure to D-cycloserine resulted in a completely degraded MucA, yet AlgU activity was not
observed within the cell, as indicated by the lack of AlgU-dependent promoter (PosmC) activity
under exposure to D-cycloserine. This lack of AlgU activity means that although MucP does not
affect the initial degradation of MucA by AlgW, seen by the loss of MucA in the mutant similar
to PAO1, the complete cleavage of MucA, and the release of AlgU, requires the cleavage by
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MucP (Wood & Ohman, 2009). Moreover, in the absence of MucD, MucP and not AlgW was
found to cleave MucA to result in mucoidy (Damron & Yu, 2011).
Finally, MucA is cleaved by a set of proteases known as ClpXP/P2. Unlike AlgW and
MucP, ClpXP/P2 cleaves the N-terminal of MucA that is located in the cytoplasm. ClpXP uses
the hydrolysis of ATP for the cleavage of MucA. ClpXP constitutes a hexamer of ClpX, an
ATPase, and ClpP a peptidase (Baker & Sauer, 2012). Moreover, ClpXP contains two PDZ
domains (Levchenko, Smith, Walsh, Sauer, & Baker, 1997) that are used to recognize the
unfolded, truncated MucA protein, sequestering AlgU, and resulting in its degradation. PAO581
is a stable mucoid strain of PAO1 with a mucA25 variant of mucA that is truncated due to a
deletion at T180, resulting in a premature stop codon at position 285. MucA25 is constituted of
94 amino acids including the 59 amino acid N-terminal of the wild type MucA (Fyfe & Govan,
1980). PAO581 mutants with mariner transposon mutagenesis at the tig, clpX, clpP (PA18001802), and a clpP paralogue clpP2 (PA3326), showed no mucoid phenotype. When the P1
promoter of algU was tested in PAO1, PAO581, and the PAO581 mutants, activity of P1 algU of
the mutant PAO581 was similar to that in PAO1, whereas the promoter activity in the wild type
PAO581 was 2.2-fold higher. The overexpression of algU in the PAO581 mutants restored the
mucoid phenotype, which proves the need for these proteases for the release of AlgU. It was
shown that neither AlgW nor MucP cleave the truncated MucA25 in PAO581 due to the lack of
the C-terminal that these proteases cleave, yet ClpXP protease activity is necessary to cleave the
cytoplasmic N-terminal of MucA (D. Qiu, Eisinger, Head, Pier, & Yu, 2008).
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Conclusion
This review shows that the CF lung is a harsh environment, associated with the CFTR
mutation that results in mucus plaques and impaired host immune response. Pseudomonas
aeruginosa takes advantage of the environment and manages to infect the patient early on, along
with other pathogens. Pseudomonas remains the dominant species in the CF lung and is the main
cause of mortality of the CF patients. The fact that a diverse and heterogeneous community
exists in the CF lungs from the hypermutators that compartmentalize the lung, makes treatment
of this infection difficult. Several sub-lineages may evolve in parallel with each other that results
in a mixture of mucoid and non-mucoid mutators strains. In addition, acute phases of
exacerbation dislodge mucus plugs and redistributes them throughout the lungs, which adds to
the heterogeneity of the infecting mass. Treatment options for CF infections would be aided by
the ability to penetrate the alginate layer in order to increase efficiency of the used drugs, as seen
in Kirby et al. (Kirby et al., 2019). Moreover, it would be important to identify the exacerbation
marker that would aid in diagnosis and treatment of the chronic lung infection.
Statement of Hypothesis
This review shows that Pseudomonas aeruginosa is a key pathogen in the CF lung and its
ability to produce alginate aids in its persistence and the deterioration of the patient’s clinical
conditions. The purpose of this dissertation is to investigate the regulation of alginate
overproduction in P. aeruginosa and develop novel treatment and diagnostic methods to target
biofilms and alginate. To that extent, we tested the following hypothesis. First, alginate
regulation is linked to de novo biosynthesis of pyrimidine and small colony variants of P.
aeruginosa through sigma factor competition. Second, the MucA variant MucA22, found in
several mucoid CF isolates, is degraded through a regulated proteolysis cascade. Last, rifaximin
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can be repurposed for use as an antibiofilm treatment in the CF lungs. In addition, a multiplex
PCR testing for the presence of pathogen-specific genesis is a viable diagnostic method to
rapidly identify and help treat lower tract respiratory infections such as those in CF patients.
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CHAPTER 2
PYRIMIDINE BIOSYNTHESIS REGULATES SMALL COLONY VARIANT AND
MUCOIDY IN PSEUDOMONAS AERUGINOSA THROUGH SIGMA FACTOR
COMPETITION
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Abstract
Mucoidy due to alginate overproduction by the Gram-negative bacterium Pseudomonas
aeruginosa facilitates chronic lung infections in patients with Cystic Fibrosis (CF). We
previously reported that disruption in de novo synthesis of pyrimidines resulted in conversion to
a non-mucoid small colony variant (SCV) in the mucoid P. aeruginosa strain (PAO581), which
has a truncated anti-sigma factor MucA25 that cannot sequester sigma factor AlgU/T. Here, we
showed that supplementation with the nitrogenous bases uracil or cytosine in growth medium
complemented SCV to normal growth, and non-mucoidy to mucoidy in these mucA25 mutants.
This conversion was associated with an increase in intracellular levels of uridine monophosphate
and triphosphate, suggesting that nucleotide restoration occurred via a salvage pathway. In
addition, supplemented pyrimidines caused an increase in activity of the alginate biosynthesis
promoter (PalgD), but had no effect on PalgU, which controls transcription of algU. Cytosolic
levels of AlgU were not influenced by uracil supplementation, yet levels of RpoN, a sigma factor
that regulates nitrogen metabolism, increased with disruption of pyrimidine synthesis and
decreased after supplementation of uracil. These results suggested that an elevated level of RpoN
in SCV may block alginate biosynthesis. To support this observation, we observed that
overexpressing rpoN resulted in a phenotypic switch to non-mucoidy in PAO581 and mucoid
clinical isolates. Furthermore, transcription of the pilA gene regulated by an RpoN-dependent
promoter increased in the mutants and decreased after uracil supplementation. These results
suggest that the balance of RpoN and AlgU levels may regulate growth from SCV to mucoidy
through sigma factor competition for PalgD.

17

Introduction
P. aeruginosa, a Gram-negative opportunistic pathogen, is associated with chronic lung
infections in patients with Cystic Fibrosis (CF) (Govan & Deretic, 1996b). There are several
bacterial species that can colonize the lungs in children with CF, however P. aeruginosa
eventually emerges as the dominant pathogen as patients grow older. The persistence of this
organism is aided by conversion to a mucoid phenotype, which renders the immune response and
antimicrobial therapies less effective (Hoiby, 2002; Ramsey & Wozniak, 2005). Alginate
production is regulated by regulatory and biosynthetic operons. The major regulatory operon
(algUmucABCD) encodes an alternative sigma factor AlgU/T (σ22), along with the cognate antisigma factor, MucA (Mathee et al., 1997; Schurr et al., 1996). The alginate biosynthetic operon
(algD) encodes most of the biosynthetic enzymes needed to convert fructose-1-phosphate into
the exopolysaccharide alginate (Rehm, 2009; Remminghorst & Rehm, 2006). MucA sequesters
AlgU to the inner membrane and through proteolysis of MucA, AlgU is released into the
cytoplasm to induce transcription at the promoters of both operons (Damron & Goldberg, 2012).
The alternative sigma factor, RpoN (σ54) (Potvin, Sanschagrin, & Levesque, 2008),
regulates nitrogen metabolism in Pseudomonas (Köhler, Harayama, Ramos, & Timmis, 1989;
Kustu, Santero, Keener, Popham, & Weiss, 1989; Shiau, Schneider, Gu, & Reitzer, 1992), as
well as the production of several virulence factors, such as motility, quorum sensing, biofilm
formation, and alginate production (Damron et al., 2012; Heurlier, Dénervaud, Pessi, Reimmann,
& Haas, 2003; Köhler et al., 1989; Lloyd et al., 2017; Thompson et al., 2003; Totten, Lara, &
Lory, 1990; Viducic, Murakami, Amoh, Ono, & Miyake, 2016, 2017). The two sigma factors
AlgU and RpoN both direct transcription of the promoter for the alginate biosynthetic operon
(PalgD), with the recognition sequences overlapping (Boucher, Schurr, & Deretic, 2000). This
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overlap suggests that a dual regulation system is present at PalgD where either AlgU or RpoN
activates alginate production under certain conditions (Boucher et al., 2000). Damron et al.
showed that deletion of RpoN in a kinB PAO1 mucoid mutant resulted in nonmucoidy and a
growth-related phenotype known as Small Colony Variant (SCV) (Damron et al., 2012).
Interestingly, like mucoidy SCV is observed in CF patients with persistent infections and is
associated with slow growth and an increase in antibiotics resistance (Evans, 2015; Haussler,
2004; Schniederjans, Koska, & Haussler, 2017).
The de novo pyrimidine biosynthesis pathway is an intricate pathway that begins with the
conversion of L-glutamate to uridine monophosphate (UMP), which is later used to synthesize
uridine triphosphate (UTP) and cytidine triphosphate (CTP) for RNA and DNA production
(O'Donovan & Neuhard, 1970). Pyrimidine synthesis is required for the regulation of several cell
functions in P. aeruginosa. For example, strains of P. aeruginosa with mutations in the
pyrimidine synthesis pathway exhibited deficiencies in production of biofilms and quorum
sensing signaling molecules, which were restored with supplementation of uracil to the media
(Beaume et al., 2015; Ralli, Srivastava, & O'Donovan, 2007; Ueda, Attila, Whiteley, & Wood,
2009). Another study showed that the activity of nucleotide diphosphate kinase (ndk) was
increased in mucoid cells compared to nonmucoid cells (Schlictman, Kubo, Shankar, &
Chakrabarty, 1995). Additionally, the level of UTP was also significantly higher in mucoid cells
than nonmucoid cells (Schlictman, Kavanaugh-Black, Shankar, & Chakrabarty, 1994;
Schlictman et al., 1995; Sundin, Shankar, & Chakrabarty, 1996). To date, no work has
specifically linked pyrimidine biosynthesis to SCV and alginate production in P. aeruginosa, and
it remains unclear how the level of cytosolic nucleotides regulates alginate overproduction.
Interestingly, the CF sputum has been shown to contain DNA at 20 mg/mL due to the eDNA
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present in the biofilms, as well as genomic DNA released when host cells are lysed (Mulcahy,
Charron-Mazenod, & Lewenza, 2008).
In this study, we showed that loss of de novo pyrimidine biosynthesis inhibited mucoidy
in the mucoid strain, PAO581 (PAO1mucA25) (Fyfe & Govan, 1980; D. Qiu et al., 2008) and
resulted in SCV. Addition of uracil to the growth media restored the colonies’ mucoid
phenotype, by restoring transcription at the alginate biosynthetic operon promoter (P algD), and the
normal colony morphology. We show that disruptions in the pyrimidine biosynthetic pathway
disrupted nitrogen metabolism in the cell, which resulted in upregulation of rpoN. Consequently,
increased levels of RpoN allowed for competition with AlgU for binding at P algD, which resulted
in inhibition of transcription of the alginate biosynthetic operon, and thus the observed loss of
alginate overproduction.
Results
Supplementation with pyrimidines restores normal growth and mucoidy in a
mucA25 mutant with mutations in the de novo pyrimidine biosynthetic pathway.
Previously, we reported that three mutations in de novo pyrimidine biosynthesis (carA,
carB, pyrD) in the mucoid strain PAO581 (PAO1mucA25) each resulted in a SCV and nonmucoid phenotype (D. Qiu et al., 2008). We thought this phenotype may be due to a link
between pyrimidine and alginate biosynthesis in P. aeruginosa. To test this hypothesis, PAO581
and the three mutants PAO581carA, PAO581carB, PAO581pyrD (all 3 mutants will be referred
to collectively as PAO581pmt- pyrimidine mutants- throughout this paper) were grown with or
without supplementation with pyrimidines. When grown on Pseudomonas isolation agar (PIA),
the pyrimidine mutants remained nonmucoid and exhibited the SCV phenotype (Fig. 1 A and B).
However, supplementation with 0.1 mM uracil (Fig. 1 A and C) or cytosine (Fig. 2 A) restored
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mucoidy and normal colony morphology. We repeated the experiment using synthetic CF
medium (SCFM2) (Turner, Wessel, Palmer, Murray, & Whiteley, 2015), which is formulated to
more closely represent the lung environment and observed similar results (Fig. 3 A). In addition,
SCFM2 and PIA were comparable in inducing mucoidy in PAO581 and a mucoid CF isolate
(Fig. 3 B and C). We used the carbazole assay to directly measure the amounts of alginate
produced by the wild-type P. aeruginosa strain PAO1, PAO581, and three mutants PAO581pmt
when grown on PIA or PIA supplemented with uracil or cytosine (Fig. 1 D). Supplementation
with either uracil or cytosine to the medium significantly increased alginate production in the
pyrimidine mutant strains compared to alginate produced on PIA alone, while supplementation
with adenine or guanine had no effect, i.e. the mutants remained SCV and non-mucoid. Clearly,
addition of free pyrimidine to the growth medium restored the growth defect and loss of alginate
production due to disruption in pyrimidine biosynthesis. These results suggest that pyrimidine
biosynthesis may be linked to alginate synthesis.
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Figure 1. The de novo pyrimidine biosynthesis is linked to the formation of SCV and
mucoidy in P. aeruginosa.
(A) Image showing PAO581 grown at 37 °C for 48h on PIA plates (left) and PIA plates with
uracil (right). (B) Image showing the effect of disrupting the de novo pyrimidine pathway in a
stable alginate-producing strain P. aeruginosa PAO581. PAO581carA, PAO581carB, and
PAO581pyrD were grown on PIA plates at 37 °C for 48 h; (C) The effect of adding uracil (0.1
mM) to the medium (PIA) on the growth of three pyrimidine biosynthetic mutants (carA, carB
and pyrD) at 37 °C for 48 h. (D) Alginate production for PAO1, PAO581, PAO581carA,
PAO581carB, and PAO581pyrD when grown on PIA plates with and without uracil at 37 °C for
24 h. Alginate was collected and measured using the standard carbazole assay. Values shown are
mean alginate ± standard deviation of triplicate reads. (E) The β-galactosidase activity of PalgD
measured using pLP170-PalgD-lacZ reporter constructs in PAO1, PAO581, PAO581carA,
PAO581carB, and PAO581pyrD grown on PIA plates containing carbenicillin and uracil at
37 °C for 24 h. Relative expression mean values shown ± standard deviation of triplicate reads.
Two-way ANOVA used with statistical significance at p< 0.01 (**** = p< 0.0001).
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Figure 2. Disruption of de novo pyrimidine biosynthesis results in loss of mucoidy.
(A) Alginate production for PAO1, PAO581, PAO581carA, PAO581carB, and PAO581pyrD
when grown on PIA plates with cytosine at 37 °C for 24 h. Alginate was collected and measured
using the carbazole assay. Values shown are mean alginate ± standard deviation of triplicate
reads. (B) The β-galactosidase activity of PalgU measured using pLP170-PalgU-lacZ reporter
constructs in PAO1, PAO581, PAO581carA, PAO581carB, and PAO581pyrD grown on PIA
plates containing carbenicillin and uracil at 37 °C for 24 h. Relative expression mean values
shown ± standard deviation of triplicate reads. Two-way ANOVA used with statistical
significance at p < 0.01 (**** = p < 0.0001).

Figure 3. Mucoid phenotype on SCFM2 media indicates that PIA medium has the same
effect on maintenance of mucoid phenotype in laboratory and clinical isolates of P.
aeruginosa.
(A) PAO581carA, PAO581carB, and PAO581pyrD grown on SCFM2 media (left) and SCFM2
media with uracil (right) at 37 °C for 24 h. (B) PAO581(top) and CF10 -mucoid CF isolate
(bottom) grown on SCFM2 media and (C) PIA at 37 °C for 24 h.
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Reduced levels of uridine monophosphate (UMP) and triphosphate (UTP) are
associated with SCV and loss of mucoidy in pyrimidine mutants.
The ability to restore the intracellular loss of pyrimidine synthesis with an extracellular
source of uracil suggested that uracil was being transported into the cells. To test this, we
measured intracellular concentrations of UMP and UTP. P. aeruginosa strains PAO1, PAO581,
and the three PAO581pmt mutants were grown on PIA or PIA supplemented with uracil. The
cytosolic fraction was collected by centrifugation and the amount of UMP/UTP in this fraction
determined by Liquid Chromatography with tandem Mass Spectrometry (LC-MS/MS). As
expected, intracellular levels of both UMP (Fig. 4 A) and UTP (Fig. 4 B) increased in the
pyrimidine mutants PAO581pmt grown on PIA containing uracil. Yet, no statistically significant
changes were observed in our control strains PAO1 and PAO581. This increase in UMP/UTP
was correlated with an increase in alginate production as determined by the carbazole assay. This
suggested that uracil was imported into cells and recycled by the pyrimidine salvage pathway,
thereby relieving the inhibitory effect of the mutations on the growth and alginate synthesis.
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Figure 4. Disruption of de novo pyrimidine biosynthesis results in reduction of intracellular
UMP and UTP and supplementation of uracil to the medium restores the levels of UMP
and UTP in P. aeruginosa.
(A) Respective P. aeruginosa strains were grown on PIA at 37 °C for 24 h. The cells of each type
in triplicate were harvested, washed, and re-suspended in PBS. The cell free lysates were used
for measurement of intracellular concentration of UMP and of (B) UTP measured using LCMS/MS. Two-way ANOVA used with statistical significance at p< 0.01 (* = p< 0.01, ** = p<
0.001, *** = p< 0.0001).
Uracil-mediated alginate activation through modulation of algD promoter activity
(PalgD).
To identify how uracil affected alginate production, we used the previously published
reporter promoter constructs PalgU_lacZ and PalgD_lacZ in pLP170 to quantify promoter activity at
the alginate regulatory operon and the alginate biosynthetic operon, respectively (Withers,
Damron, Yin, & Yu, 2013). After introducing the constructs into PAO1, PAO581, and our three
mutants PAO581pmt, the strains were grown on either PIA or PIA supplemented with uracil, and
we used the β-galactosidase activity assay to quantify the activity of both P algU (Fig. 2 B) and
PalgD (Fig. 1 E). The promoter activity at PalgU was not affected by the disruption of pyrimidine
biosynthesis, nor the addition of uracil to the media. Conversely, the activity at PalgD in the three
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mutants PAO581pmt was relatively low when grown on PIA, but promoter activity was
increased upon addition of uracil to the media. Thus, loss of pyrimidine biosynthesis decreased
promoter activity at the alginate biosynthesis operon (algD operon), but not the regulatory
operon (algU operon).
Inactivation of de novo pyrimidine biosynthetic pathway increases RpoN (σ54).
Pyrimidine starvation increases the levels of an alternative sigma factor, RpoN, due to the
disruption of nitrogen metabolism (Hunt & Magasanik, 1985; Kustu et al., 1989; Shiau et al.,
1992). We hypothesized that an increase in RpoN might disrupt the balance between sigma
factors RpoN and AlgU. Since RpoN and AlgU have overlapping binding sites at PalgD, RpoN
could now outcompete AlgU for binding to PalgD, leading to loss of alginate biosynthesis
(Boucher et al., 2000). To test whether loss of pyrimidine biosynthesis affected sigma factor
levels, we performed western blots to analyze the intracellular amounts of RpoN and AlgU (Fig.
5 and 6). In the PAO581 pyrimidine mutant strains, RpoN was present at relatively higher levels
than in PAO581, and addition of uracil to the media decreased RpoN. On the other hand, AlgU
levels in the pyrimidine mutants PAO581pmt were similar to the parent PAO581 strain, and
upon the addition of uracil AlgU remained relatively consistent. Thus, loss of de novo pyrimidine
biosynthesis resulted in the upregulation of RpoN and adding uracil to the media reduced RpoN
levels but did not affect the levels of AlgU.
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Figure 5. The effect of the de novo pyrimidine pathway on intracellular levels of RpoN.
RpoN levels from PAO581, PAO581carA, PAO581carB, and PAO581pyrD grown on PIA
plates and PIA plates with uracil at 37 °C for 24 h from three separate WES runs using antiRpoN antibody normalized by Total Protein levels. Values shown are of mean ratio ± standard
deviation. Two-way ANOVA used with statistical significance at p<0.01 (* = p<0.01, ** = p<
0.001, ****=p<0.0001).

Figure 6. Disruption of de novo pyrimidine biosynthetic pathway does not affect the levels
of free AlgU in the cytosol.
AlgU levels from PAO581, PAO581carA, PAO581carB, and PAO581pyrD grown on PIA plates
and PIA plates with uracil at 37 °C for 24 h from three separate WES runs using anti-AlgU
antibody normalized by Total Protein levels. Values shown are of mean ratio ± standard
deviation. Two-way ANOVA used with statistical significance at p < 0.01 (* = p < 0.01).
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Transcription of PpilA is altered by disruption in pyrimidine biosynthesis due to
increased RpoN levels.
Previously, Withers et al. showed that transcription of PpilA is regulated by RpoN
(Withers et al., 2013). To test whether the pyrimidine biosynthesis is linked to the RpoN
regulation, we measured the promoter activity of PpilA_lacZ in pLP170 (Withers et al., 2013) in
PAO1, PAO581, and our three mutants PAO581pmt (Fig. 7). A significant increase in PpilA
promoter activity was observed in the mutants as compared to PAO581. When the PAO581pmt
mutants were grown on uracil-supplemented media the promoter activity decreased and was
similar to that in PAO581 on PIA with uracil. This observation supports our results that cytosolic
RpoN levels are increased in the mutants which in turn lead to inhibit the alginate biosynthesis.

Figure 7. Transcriptional activity of RpoN-dependent type IV pilin promoter PpilA was
increased in pyrimidine biosynthesis mutants compared to the parent PAO581 .
The β-galactosidase activity of PpilA measured using pLP170-PpilA-lacZ reporter constructs in
PAO1, PAO581, PAO581carA, PAO581carB, and PAO581pyrD grown on PIA plates
containing carbenicillin and uracil at 37 °C for 24 h. Relative expression mean values shown ±
standard deviation of triplicate reads. Two-way ANOVA used with statistical significance at p <
0.01 (**** = p < 0.0001).
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Overexpression of RpoN in PAO581 reduced transcriptional activity at PalgD but not
at PalgU.
Previously, Yin et al. (Y. Yin, Withers, Wang, & Yu, 2013) showed that overexpression
of rpoN in PAO581 resulted in the loss of mucoidy, suggesting there is sigma factor competition
between AlgU and RpoN. Boucher et al. showed that RpoN has a binding sequence at PalgD and
inactivation of RpoN in muc23 strain resulted in loss of transcription from P algU (Boucher et al.,
2000). To test how RpoN affects alginate production, we overexpressed RpoN and measured
promoter activity at the regulatory and biosynthetic alginate operons. To do this, we conjugated
the pHERD20T vector carrying rpoN into PAO581 with the PalgU-lacZ and PalgD-lacZ inserted at
the CTX site on the chromosome (Damron, Qiu, & Yu, 2009) (Fig. 8 B and C). The activity of
both promoters was tested when PAO581 was grown on PIA or PIA supplemented with
arabinose at increasing concentrations (0.05%, 0.1%, 0.5%) to induce rpoN expression. Activity
at PalgU was not affected by the overexpression of rpoN. However, the activity at PalgD decreased
as the RpoN levels increased in the cell in a concentration dependent manner. These results
suggested that increased levels of RpoN may lead to increased RpoN binding to P algD and loss of
the mucoid phenotype in PAO581. To test whether the loss of mucoidy observed with
overexpression of RpoN might be a strain-specific effect, we overexpressed RpoN in PAO579
(muc-23) and in two stable mucoid CF isolates CF10 and C7447 (Fig. 9). All three strains
exhibited reduction in mucoidy similar to our observations in PAO581.
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Figure 8. Overexpression of RpoN suppresses mucoidy through interference with PalgD but
not PalgU in P. aeruginosa PAO581.
(A) Image of PAO581 carrying empty vector pHERD20T (left) and pHERD20T-rpoN (right)
grown on a PIA plate with carbenicillin and 0.1% arabinose at 37 °C for 24 h. (B) The βgalactosidase activity of PalgU and of (C) PalgD using PalgU-lacZ and PalgD-lacZ reporter system
shuttled in the chromosome of PAO581 via mini-CTX. These two strains were introduced
pHERD20T (control) and pHERD20T-rpoN. Strains grown on PIA plates with tetracycline,
carbenicillin, and varying concentrations of arabinose (0.05%, 0.1%, 0.5%) at 37 °C for 24 h.
Values shown are mean relative expression ± standard deviation performed in triplicates. Oneway ANOVA used with statistical significance of p < 0.01.

Figure 9. Overexpression of rpoN results in reduction of mucoidy in CF isolates and
PAO579.
Image showing (A) PAO579, and stable mucoid CF isolates (B) CF10 and (C) CF7447 carrying
pHERD20T (left) and pHERD20T-rpoN (right) grown on PIA plates with carbenicillin and 1%
arabinose at 37 °C for 36 h.
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Pyrimidine mutants can become mucoid through overexpression of AlgU.
To investigate if the PAO581pmt mutants can still produce alginate regardless of the
mutations in the pyrimidine pathway and overcome the higher levels of RpoN, algU was
overexpressed in PAO1, PAO581 and the three pyrimidine mutants PAO581pmt using the
pHERD20T-algU plasmid. After growing the pyrimidine mutants PAO581pmt carrying the
pHERD20T-algU plasmid on PIA supplemented with 0.1% arabinose, the mucoid phenotype
was restored without the need to supplement the media with pyrimidines (Fig. 10). This result
shows that by overexpressing algU, mucoidy can be returned regardless of pyrimidine starvation
and suggesting a restoration in the balance of RpoN and AlgU.

Figure 10. Overexpressing algU leads to mucoidy in the pyrimidine biosynthesis mutants.
Image showing the effect of overexpressing algU on the growth of PAO1, PAO581,
PAO581carA, PAO581carB, and PAO581pyrD carrying empty vector pHERD20T (left) and
pHERD20T-algU (right) grown on PIA with carbenicillin and 0.1% arabinose at 37 °C for 24 h.
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Generation of in-frame deletions of pyrD in PAO1 and PAO581.
Our work showed that disruption in de novo pyrimidine synthesis results in SCV
phenotype. To identify if the transposon disruption of the pyrimidine pathway was polar, we inframe deleted the pyrD gene in PAO1 and PAO581 resulting in SCV for PAO1 and nonmucoidy and SCV for PAO581. The addition of free uracil to PAO1ΔpyrD results in the return
of the normal phenotype of PAO1 but does not induce mucoidy (Fig. 11 A and B). Similar to
PAO581pyrD, PAO581ΔpyrD also becomes mucoid when grown on PIA with uracil (Fig. 11 C
and D). These results show that the phenotype of the transposon mutants was true and was
unrelated to the method by which the mutants were generated.

Figure 11. In-frame deletion of pyrD results in SCV in PAO1, and SCV and non-mucoid
phenotype in PAO581.
(A) Image shows PAO1 (left) and PAO1ΔpyrD (right) grown on PIA plates and (B) PIA plates
with uracil at 37 °C for 24 h. (C) Image shows PAO581 (left) and PAO1ΔpyrD (right) grown on
PIA plates and (D) PIA plates with uracil at 37 °C for 48 h.
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Discussion
The presence of alginate in the lungs of CF patients hinders the function of the patient’s
immune system and the efficacy of the antimicrobial therapy. A better understanding of the
regulation of alginate production would aid in development of pharmaceuticals that target the
process and eventually eliminate the sources of chronic lung infections. Our previous work (D.
Qiu et al., 2008) showed that loss of the de novo pyrimidine biosynthesis resulted in loss of
mucoidy in an otherwise mucoid P. aeruginosa strain, PAO581. There has been little work
investigating the relationship between de novo pyrimidine biosynthesis and alginate biosynthesis.
Here, we aimed to map the link between these pathways to identify new targets for anti-alginate
therapies.
In this study, we found that the addition of free uracil or cytosine to the medium restored
the mucoid phenotype in PAO581 pyrimidine mutants, likely through the pyrimidine salvage
pathway. This effect appears to be pyrimidine-specific, as the addition of purine bases to the
media had no effect on the phenotype of these pyrimidine mutant strains. To show that the
addition of uracil is linked to the return of mucoidy by stimulating the pyrimidine salvage
pathway, we used LC-MS/MS to measure the intracellular UMP and UTP concentration. UMP is
the common end-product of both de novo and salvage pathways. Intracellular concentrations of
UMP in the three pyrimidine mutants was lower than that in PAO581 when grown on PIA;
however, when the medium was supplemented with uracil, intracellular UMP and UTP
concentrations were restored to PAO581 levels. These findings indicated that the addition of
uracil stimulated the pyrimidine salvage pathway, which in turn restored the mucoid phenotype.
This result is consistent with early observations that mucoid strains were associated with higher
levels of intracellular nucleotides (Schlictman et al., 1994; Schlictman et al., 1995).
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Alginate biosynthesis in P. aeruginosa occurs via two main operons, the regulatory
algUmucABCD, and the biosynthetic algD operons. We used promoter reporter fusion plasmid to
measure transcriptional activities from both operons to identify the level at which the loss of
pyrimidine biosynthesis affected the alginate pathway. The promoter activity of the algU operon
was not affected by the loss of pyrimidine synthesis nor was the activity changed when the
strains were grown in the presence of uracil. Therefore, regulation of the algU promoter is not
affected by intracellular pyrimidine concentration. Importantly, the normal algU promoter
activity showed that loss of pyrimidine biosynthesis does not cause a universal decrease in
transcription, which would be expected to cause a reduction in alginate production. On the other
hand, PalgD exhibited a significant decrease in activity in the three PAO581 mutants compared to
the parent. When uracil was added to the media, promoter activity was restored to levels
comparable to the activity observed in PAO581. This increase in promoter activity was
concurrent with the return of mucoidy in all three pyrimidine mutant strains, suggesting a direct
relationship between intracellular pyrimidine concentration and P algD activity.
Boucher et al. found that AlgU and RpoN have overlapping binding sequences at P algD, and that
overexpression of rpoN inhibited mucoidy in PAO578 (Boucher et al., 2000). However, the
muc23 mutation was later characterized to be pilA108, which produced a truncated type IV pilin
with FTF tail at C-terminus of PilA108 to activate AlgW, which initiate the proteolytic cascade
to degrade the full-length of MucA (R. Li et al., 2016). Similarly, Yin et al. reported that
overexpression of rpoN using pHERD20T resulted in the loss of mucoidy in PAO581 (Y. Yin,
T.R. Withers, X. Wang, & H. Yu, 2013). RpoN is a sigma factor that regulates expression of
numerous important genes which control virulence, stress response, motility, and metabolism
among other functions (Cai et al., 2015; Köhler et al., 1989; Lloyd et al., 2017; Totten et al.,
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1990; Viducic et al., 2016, 2017). Our Western blot results showed that the levels of RpoN
increased in the PAO581pmt mutants and were restored to PAO581 levels after the addition of
uracil. On the contrary the levels of AlgU remained unchanged before and after uracil induction
in the PAO581pmt mutants. This observation suggests that RpoN binding to the promoter was
probably the major inhibitory factor in the loss of mucoidy in the pyrimidine mutants. However,
proteolysis of MucA25 is significant in the augmentation of alginate in the parent strain because
the alginate production was increased significantly when uracil was used. It is likely that
disruption in the pyrimidine de novo synthesis results in disruption in the nitrogen metabolism in
the cell, which is regulated by RpoN (Hunt & Magasanik, 1985; Kustu et al., 1989; Shiau et al.,
1992). To resolve this disruption, rpoN is upregulated in the mutants, as verified by our western
blot analyses. This increase in RpoN disrupts the RpoN/AlgU balance, leading to competition
with AlgU for binding at PalgD. Moreover, the effect of the increased RpoN levels is evident by
the increased promoter activity of PpilA in the pyrimidine mutants, which is restored to levels
comparable to the wild type PAO581 strain when uracil is added to the media (Fig 7). With the
addition of free uracil to the media the mucoid phenotype returned, along with a decrease in
RpoN levels and an increase in UMP/UTP. So, addition of uracil to the media restores
intracellular pyrimidine levels by supplementing the salvage pathway and relieves the stress
presented on the nitrogen cycle. Moreover, upon overexpression of algU using pHERD20T, we
observed a return of the mucoid phenotype without the need to supplement the media with uracil.
This observation shows that by artificially increasing the levels of AlgU in the cell, it can out
compete RpoN for the PalgD site which is shown by the increase of PalgD promoter activity and
consequentially return in mucoidy. These results show that there is an important balance between
AlgU and RpoN levels in Pseudomonas, with AlgU at those normal levels being the dominant
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sigma factor (Hershberger, Ye, Parsek, Xie, & Chakrabarty, 1995) binding and activating PalgD.
By deleting the pyrimidine biosynthesis enzymes, RpoN is overexpressed to overcome the lower
levels of pyrimidine, and thereby becoming the dominant sigma factor due to its higher levels.
In-frame deletion of pyrD in PAO1 resulted in SCV and uracil restored the normal colony
morphology. In PAO581 similar deletion resulted in both SCV and non-mucoidy, and the
addition of uracil restored both phenotypes. In the case of PAO1ΔpyrD, addition of uracil only
returns SCV to normal phenotype because mucA is still wild type. These details show that two
separate phenotypes are found with these gene deletions; first is the SCV due to pyrimidine
starvation resulting in overexpression of rpoN. The second phenotype is the loss of mucoidy due
to the increased levels of RpoN that competes with AlgU for binding to PalgD.
Antibiotic sensitivities were tested for the PAO581pmt mutants using the standard disc
diffusion assay on PIA and PIA with uracil (Tables 1 and 2). Our results showed that compared
to PAO581, the PAO581pmt mutants were statistically more sensitive to all eight antibiotics
tested (Aztreonam, Meropenem, Imipenem, Ceftazidime, Cefepime, Levofloxacin,
Ciprofloxacin, Tobramycin) (Table 1). However, addition of uracil cannot restore the level of
antibiotic sensitivity despite the restoration of normal growth rate in mutants (Table 2). This
finding suggests that the pyrimidine biosynthetic enzymes may have a previously unknown
function that mediates the resistance to antibiotics. Further studies need to be performed to test
this possibility.
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Aztreonam* Meropenem* Imipenem* Ceftazidime Cefepime* Levofloxacin Ciprofloxacin Tobramycin
PAO581
19.7
25.0
22.0
19.3
20.3
17.0
20.3
9.3
PAO581ΔalgD
24.0
29.5
30.5
19.5
21.5
14.5
22.0
11.5
PAO581carA
23.3
27.7
34.0
25.3
25.3
26.0
29.7
17.0
PAO581carB
25.3
32.3
34.7
27.0
29.0
25.7
28.3
14.0
PAO581pyrD
32.3
30.3
36.0
34.0
27.7
20.0
25.0
18.7
Table 1: Zone of inhibition (mm) for strains grown on PIA with indicated antibiotic disk.
Antibiotic disk diffusion assay performed using BD Sensi-Disc ™ according to the standard protocol. Values shown are of the average
zone (mm) ± standard deviation for each strain when grown on PIA at 37 °C for 24h with the indicated disk measured in triplicates.
Two-way ANOVA with multiple comparisons was used to calculate the statistical significance with p<0.01 (**=p<0.001,
****=p<0.0001).

Aztreonam* Meropenem* Imipenem* Ceftazidime Cefepime* Levofloxacin Ciprofloxacin Tobramycin
PAO581
19.3
25.7
23.7
18.7
20.7
18.3
22.3
10.3
PAO581ΔalgD
20.0
27.0
23.5
19.5
21.5
19.0
20.0
9.0
PAO581carA
30.7
31.7
27.0
25.7
27.0
25.3
33.3
16.7
PAO581carB
29.7
36.3
34.7
29.7
29.7
26.0
27.7
15.0
PAO581pyrD
34.0
35.0
35.0
34.3
33.0
17.7
25.0
18.7
Table 2: Zone of Inhibition (mm)4 for strains grown on PIA with uracil with indicated antibiotic disk.
Antibiotic disk diffusion assay performed using BD Sensi-Disc ™ according to the standard protocol. Values shown are of the average
zone (mm) ± standard deviation for each strain when grown on PIA with uracil at 37 °C for 24h with the indicated disk measured in
triplicates. Two-way ANOVA with multiple comparisons was used to calculate the statistical significance with p<0.01
(****=p<0.0001).
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Our results showed that free uracil induced mucoidy in pyrimidine mutants PAO581pmt
through mechanisms independent of PalgU transcriptional activity. Therefore, the activation of
AlgU to induce mucoidy is likely post-translational. AlgU is regulated post-translationally
through the proteolytic degradation of MucA, PAO581 has a truncated MucA variant, MucA25
(D. Qiu et al., 2008), which is rapidly degraded by intracellular proteases ClpXP. While adding
uracil to the medium induced a higher level of AlgU in the parent PAO581, which corresponds
to more alginate production (Fig. 1D), there was no statistically significant difference in the
levels of AlgU between untreated vs. treated mutants. This result seems to indicate that alteration
of proteolytic degradation of MucA25 in the PAO581pmt mutants was less likely. It is more
likely that loss of RpoN-mediated inhibition at PalgD is responsible for the uracil-mediated
alginate induction in the mutants. Another explanation is that RpoN has a secondary effect on
mucoidy. Over-expressing RpoN results in loss of PalgD activity and subsequently loss of
mucoidy; this may be due an inhibitor regulated by RpoN that is causing the observed effects
rather than a direct inhibition exhibited by RpoN.
Our work demonstrates that there is an indirect link between de novo pyrimidine
synthesis and alginate biosynthesis through regulation of sigma factor levels. The disruption of
the de novo pyrimidine pathway results in increased levels of RpoN and causes a loss of mucoidy
in PAO581. Addition of free uracil to the media results in a return to normal pyrimidine levels,
causing a decrease in the RpoN levels and thereby return of mucoidy. Similarly, overexpression
of algU causes the balance between AlgU and RpoN to shift to favor AlgU and the mucoid
phenotype (Fig. 12). Overall, our findings demonstrate that both sigma factors need to exist in a
balanced state to maintain the desired phenotype. A possible explanation to the existence of the
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dual regulation system at PalgD is to regulate cellular energy under stress to essential pathways
necessary for cellular survival and away from the energy expensive alginate synthesis.

Figure 12. Schematic showing the link between de novo pyrimidine synthesis, SCV and
alginate biosynthesis through sigma factors RpoN and AlgU competition for P algD.
(A) Shows that disruption in the pyrimidine de novo biosynthetic pathway results in decreased
levels of UMP. This causes an increase in RpoN that competes with AlgU to bind to the algD
promoter (PalgD) and thereby inhibiting alginate production. (B) The addition of free uracil to the
media causes the levels of UMP to increase through salvage pathway and thereby the levels of
RpoN decrease, which allows AlgU to bind to the algD promoter (PalgD) and this results in
alginate production. Moreover, overexpression of algU using pHERD20T and arabinose results
in increased AlgU in the cell that out-competes RpoN and results in alginate production.
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Materials and Methods
Bacterial strains, plasmids, and growth conditions.
All bacterial strains used in this study are listed in Table 3. P. aeruginosa strains were all
grown on Pseudomonas Isolation Agar (PIA) plates (Difco, Detroit, MI) or Pseudomonas
Isolation Broth (PIB) (Difco, Detroit, MI) at 37 °C, prepared by adding 20 mL of glycerol/liter of
media as per manufacturer recommendation. PIA was supplemented with 300 μg/mL of
carbenicillin (RPI, Mt. Prospect, PA), 0.1%/1% of arabinose (MP Biomedicals, Solon, OH) by
weight, 10% sucrose (Fisher Scientific, Waltham, MA) by weight, or 0.1 mM of nitrogenous
bases (adenine, cytosine, guanine, and uracil) (Arcos Organics, Morris, NJ) when necessary. All
Escherichia coli strains were grown in Lennox Broth (LB) (Difco, Detroit, MI) or on LB agar
plates, and supplemented with 100 μg/ml. of carbenicillin or 50 μg/ml. of Kanamycin (RPI, Mt.
Prospect, PA) when needed. Synthetic CF Media (SCFM2) was prepared according to the
protocol cited in Turner et al. (Turner et al., 2015) with 0.1 mM of uracil (11 μg/mL)
supplemented when necessary.
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Bacterial Strain/ plasmid
P. aeruginosa Strains
PAO1
PAO579
PAO581
PAO581 carA::aacC1
PAO581 carB::aacC1
PAO581 pyrD::aacC1
PAO581 algD::aacC1
PAO1ΔpyrD
PAO581ΔpyrD
CF001
CF10
C7447
E. coli Strains
TOP10
Plasmids
pRK2013
pHERD20T
pHERD20T-algU
pHERD20T-rpoN
pEX100T-NotI
pEX100T-NotI-ΔpyrD
pLP170
pLP170-PalgU
pLP170-PalgD
pLP170-PpilA
MiniCTX-lacZ
MiniCTX-PalgU-lacZ
MiniCTX-PalgD-lacZ

Genotype, phenotype, or description

Source or reference

Prototroph, NM
PAO381 derivative with muc-23 (pilA23 resulting in PilA108), M
PAO1 mucA25, M
PAO581DR68/ PAO581 carA::Gmr, NM, SCV
PAO581DR26/ PAO581 carB::Gmr, NM, SCV
PAO581DR50/ PAO581 pyrD::Gmr, NM, SCV
PAO581DR1/ PAO581 algD::Gmr, NM
PAO1 with in-frame deletion of pyrD, NM, SCV
PAO581 with in-frame deletion of pyrD, NM, SCV
CF isolate, M
CF isolate, M
CF isolate, M

P. Phibbs*
J. Govan **
J. Govan **
(D. Qiu et al., 2008)
(D. Qiu et al., 2008)
(D. Qiu et al., 2008)
(D. Qiu et al., 2008)
This study
This study
M. Anstead***
(Head & Yu, 2004)
(Yeshi Yin, Withers,
Johnson, & Yu, 2013)

DH5α Derivative

Invitrogen

Kmr, Tra Mob ColE1
pUCP20T Plac replaced with 1.3-kb AflIII-EcoRI fragment of araC-PBAD cassette

(Figurski & Helinski, 1979)
(Dongru Qiu, Damron, Mima,
Schweizer, & Yu, 2008)
(D. Qiu et al., 2008)
(Damron et al., 2009)
(Damron et al., 2009)
GeneScript
(Preston et al., 1997)
(Withers et al., 2013)
(Withers et al., 2013)
(Withers et al., 2013)

algU (PA0762) from PAO1 in pHERD20T (pBAD/pUCP20), XbalI/HindIII
rpoN (PA4462) from PAO1 in pHERD20T, XbaI/HindIII
Suicide Vector with NotI restriction site fused into SmaI of pEX100T, sacB, oriT, Cbr
1.2-kb flanking pyrD (PA3050) gene ligated into pEX100T-NotI with in-frame deletion of pyrD
8.3-kb, promoterless-lacZ, Apr, multiple cloning site
Complete PalgU promoter (541 bp upstream of ATG) fused with lacZ in pLP170 BamHI/HindIII
Complete PalgD promoter (989 bp upstream of ATG) fused with lacZ in pLP170 BamHI/HindIII
Complete PpilA promoter (500 bp upstream of ATG) fused with lacZ in pLP170
BamHI/HindIII
Gene delivery vector for inserting genes at the CTX phage att site on the
P. aeruginosa
chromosome; Tcr
Complete PalgU promoter (541 bp upstream of ATG) EcoRI/HindIII fused with lacZ for integration at the
CTX phage att site in P. aeruginosa
Complete PalgD promoter (1,525 bp upstream of ATG) HindIII/BamHI fused with lacZ for integration at
the CTX phage att site in P. aeruginosa

(Hoang, Kutchma, Becher, &
Schweizer, 2000)
(Damron et al., 2009)
(Damron et al., 2009)

Table 3. Bacterial Strains and plasmids used in this study.
*P. Phibbs, East Carolina University, Greenville, NC. **J. Govan, University of Edinburgh, Scotland, U.K. ***M. Anstead, University of
Kentucky Department of Pediatrics, Lexington, KY; NM=Non-mucoid; M=Mucoid; SCV=Small Colony Variant.
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Genomic DNA, Plasmid and Protein extractions.
Bacterial Genomic DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen,
Germantown, MD) from 1x109 CFU/mL of cells grown in PIB or LB broth at 37 °C for 24 h.
Plasmids were extracted using the QIAprep Spin MiniPrep Kit (Qiagen, Germantown, MD) from
1x10^8 CFU/mL of cells grown in LB containing the necessary selective antibiotics at 37 °C for
24 h. The plasmid DNA was extracted using the provided protocol. DNA concentrations were
measured using a NanoDrop ND-1000 Spectrophotometer (Thermo Fisher Scientific, Waltham,
MA). Whole cell proteins were extracted using the NoviPure Microbial Protein Kit (Mo Bio,
Carlsbad, CA /Qiagen, Germantown, MD). Cells were grown on PIA plates containing the
necessary selection media supplement. Plates were scraped into 1x Phosphate Buffered Saline
(PBS) and 1x108 CFU/mLof cells were pelleted and used to extract the whole cell protein using
the protocol provided with the kit. Proteins were eluted in 100 μL of PE elution buffer. Protein
concentration was measured using the BCA Protein Assay kit (Thermo Fisher Scientific,
Waltham, MA) and the Optical Density (OD) read on the SpectraMax i3x (Molecular Devices,
Downingtown, PA) at 562nm. All extracted samples were stored at -20 °C.
Polymerase Chain Reaction.
All PCR reactions were run using the Hot Start Taq 2X Master Mix (New England
Biolabs, Ipswich, MA). 25μL of the master mix was mixed with 1μL of each primer and 23μL of
DNA + DNase/RNase free water. Themocycling reaction conditions were: 95 °C for 30 sec. for
initial denaturation, 30 cycles of (95 °C for 30 sec., 58 °C for 30 sec., and 68 °C for 60 sec.), and
a final extension of 68 °C for 5 minutes, and then samples were held at 4 °C.
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Conjugation.
Pseudomonas strains that were used to acquire the plasmid were grown from a purified
culture in LB broth at 42 °C for 24 h. The plasmid containing E. coli were grown in LB broth at
37 °C for 24 h. 300 μL of each of the three strains (donor strain containing the plasmid, E. coli +
pRK2013, and recipient strain) were mixed in a 1.7 mL sterile elution tube. Tube was vortexed
on high for 15 seconds using a benchtop vortex. The tube was then centrifuged at 17,900 xg for 3
minutes to obtain a cell pellet. The supernatant was discarded, and the pellet was re-suspended in
the remaining 50μL of supernatant, and then was blotted on an LB plate that was dried for 30
minutes at 37 °C. The LB plate containing the blot was left face-up to dry under hood and once
dry the LB plate was covered and placed in the incubator face down at 37 °C for 6 hours. Half
the blot was streaked using an inoculating loop on PIA plates containing selective antibiotics
(carbenicillin 300 μg/mL with/without gentamicin 150 μg/mL depending on the strain) and let
incubate at 37 °C for 24 h. Single colonies were selected from the PIA plate and isolated on
selective PIA plates twice to obtain single colony isolates.
Transformation.
Transformations were performed with TOP10 electrocompetent cells (Invitrogen,
Carlsbad, CA). 2-5 μL of plasmid was mixed with 50 μL of E. coli cells (TOP10) thawed on ice
and mixed. Samples were electrically shocked and 250 μL of S.O.C. media was added to the
cells and let shake at 37 °C for 1-2 hours in a 1.7 mL elution tube. 10 μl, 50 μl, and the pellet
were then spread on Luria agar plates containing 100 μg/mL of carbenicillin and grown at 37 °C
for 24 h.
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In-Frame gene deletion.
In-frame deletions were conducted using pEX100TNotI-ΔpyrD through a two-step
allelic exchange procedure. Single-crossover merodiploid strains were selected based on
sensitivity to sucrose (sacB) and resistance to carbenicillin. Selected merodiploid strains where
then grown in LB broth at 37 °C. Double-cross over strains were selected based on sensitivity to
carbenicillin and confirmed through PCR amplification of the flanking region of target gene.
Alginate assay.
The method is also referred to in this study as carbazole assay. Strains were grown in PIB
at 37 °C to a McFarland turbidity of 0.5 (1.5x108 CFU/mL), 450 μL of the broth was then spread
on 150mm x10mm petri dishes (Fisherbrand, Waltham, MA) containing 50 mL of PIA, or 50 mL
of PIA containing the respective supplement (0.1mM of nitrogenous bases). Plates were grown at
37 °C for 24 h. Using 30 mL of 0.85% NaCl solution the colonies were scraped and placed in a
50 mL conical tube on ice. 3 mL of 18M sulfuric acid/ borate solution was aliquoted into culture
tubes and placed on ice. 350 μL of the collected sample was added in triplicates to culture tubes
containing the sulfuric acid/ borate solution, and then briefly vortexed. 100 μL of 0.1% carbazole
(Sigma-Aldrich, St. Louis, MO) in ethanol was added to the tubes and then vortexed for 5
seconds. Tubes were then incubated at 55 °C for 30 minutes. OD600 of the initial collected
samples and OD530 of the culture tubes were read. Using a standard curve, the total alginate
concentration per OD600 was then calculated using the formula below.
[alginate concentration] / OD600
β-Galactosidase assay.
Strains carrying the lacZ fusion were streaked on PIA or PIA supplemented with 0.1 mM
uracil at 37 °C for 24 h. The colonies were then scraped into 4 mL1x PBS and then diluted to
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OD600 0.3-0.7. Triplicates of 100 μL of the sample were added to 900 μL of Z-buffer and 20 μL
toluene in a 1.5 mL elution tube. After mixing by inverting 4-5 times tubes were placed with tops
open in a shaking incubator at 37 °C for 40 minutes. After, 200 μL of ortho-Nitrophenyl-βgalactoside (ONPG) (4 mg/mL) (Thermo Scientific, Waltham, MA) was added and the time of
color change was recorded, the reaction was stopped by adding 500 μL of 1 M Na2CO3 (Fisher
Scientific, Waltham, MA) after 20 minutes. OD420 and OD550 were measured using a SpectraMax
i3x (Molecular Devices, Downingtown, PA) plate reader. Miller units were calculated using the
following formula:
1000x [OD420 – (1.75 x OD550)] / [color change time (min.) x Sample volume x OD600]
Liquid Chromatography –Mass Spectrometry Measuring Intracellular levels of
UMP/UTP.
All Strains were grown on PIA or PIA supplemented with 0.1mM uracil for at 37 °C for
24 h. Using 1x PBS, the colonies were scraped off the plates and centrifuged at 6800 xg for 5
minutes to obtain 100 mg pellets which were shipped on dry ice to the Proteomics & Mass
Spectrometry Facility at the Danforth Plant Science Center (St. Louis, MO). A total of 10
samples in triplicate were analyzed using LC-MS. The samples were extracted in 200 μL 80%
methanol containing 10 μM of the internal standards, 15N2, 13C9 UMP and 15N2, 13C9 UTP by
vortexing for 10 minutes. Samples were centrifuged then filtered through 8.0 μm PES spin filters
to remove particulates. Samples (1 μl) were loaded onto a 0.5 x 100 mM custom packed
Proteomix-SAX column using 250 mM ammonium carbonate in water (A) and 25% methanol
(B). The gradient started at 100%B for three minutes followed by a ramp to 100%B over ten
minutes with a hold at 100%B for a minute then ramp back down to 100%B over one minute.
The column was then re-equilibrated for 15 minutes. Data were recorded in negative ion mode
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using a Q-Exactive mass spectrometer set to a resolution setting of 140,000 (at m/z 200) with a
scan range of 200-700. The data were integrated using the QuanBroswer application of Xcalibur.
The concentrations were calculated based on comparison to the internal standards and plotting
against a calibration curve made from various concentrations of unlabeled standards and constant
concentration of isotope labeled standards (10 μM).
Western Blot.
Whole cell lysate extracted using NoviPure Microbial Protein Kit, were used to run
western blots on the Protein Simple WES System (ProteinSimple, San Jose, CA). Samples were
diluted to 250 μg/mL using 0.1x Sample Buffer and mixed with 5x Fluorescent Master Mix at
4:1 ratio and denatured at 95 °C for 5 minutes. Samples were then loaded (3 μl) into the Wes
plate (Wes 12-230 kDa prefilled plate) with the first lane containing 5 μL of the biotinylated
protein ladder provided along with blocking reagent, primary antibodies, ProteinSimple HRPconjugated anti-mouse secondary antibody, luminol peroxide, and washing buffer. The primary
antibodies used were Anti-AlgU (6C6) (Schurr et al., 1996) and Anti-RNA σ54 (RpoN)
(BioLegend, San Diego, CA) mouse IgG monoclonal antibodies dilutions of 1:20 and 1:1000
respectively. The Wes plate was run using the Wes default settings: 27 min. separation time at
375 Volts, blocking with Antibody Diluent 2 for 5 min. (30 min. for Total Protein Assay),
primary antibody for 30 min., secondary for 30 min., and exposure times ranging from 1 sec. to
120 sec. Gel images were generated and results were analyzed on the Compass for Simple
Western software (ProteinSimple, San Jose, CA) version 3.1.7.
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Statistical Analysis.
The unpaired two-tail student t test, one-way and two-way ANOVA were run with
statistical significance set at p < 0.01. All statistical analysis was done using GraphPad Prism
version 7.02 for windows (GraphPad Software, La Jolla, CA).
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Abstract
Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause chronic
lung infection in patients with Cystic Fibrosis (CF). Overproduction of the exopolysaccharide
alginate by P. aeruginosa aids its ability to persist in the lungs of patients with CF. Mutations
that inactivate the anti-sigma factor MucA are a major mechanism that result in loss of
sequestration of the master alginate regulator AlgU/T that in turn activates the transcription of
alginate biosynthetic operon. However, it is not clear how the regulated proteolysis fits in this
paradigm. In this study, an hemagglutinin epitope (HA) tagged mucA22 cloned on the expression
vector pHERD20T was used for further characterization of the degradation of MucA22 in
various PAO1 strains carrying mutations in genes of MucA proteases, such as AlgW, MucP, and
ClpP. It was also shown that the overexpression of the proteases in PAO1 and PDO300 does not
affect their respective phenotypes. Using a Pseudomonas suicide vector pEX100Not, we made
two mucA strains with the hemagglutinin epitope tagged to the N- terminus of the MucA,
producing two strains, PAO1 HA-mucA and PAO1 HA-mucA22. PAO1 HA-mucA is nonmucoid
while PAO1 HA-mucA22 is mucoid, similar to PAO1 and PDO300, respectively. Moreover, it
was shown that N-terminal tags on MucA do not affect its function nor hinder its proteolytic
degradation. This work would facilitate mapping of the proteolytic degradation of MucA
proteins and establish the link between proteolysis and MucA mutations in regulating alginate
overproduction in P. aeruginosa.
Introduction
Cystic Fibrosis (CF) is a genetic illness that results in mucus plugs in the patient lungs
that enable bacteria like Pseudomonas aeruginosa to attach in the lungs and cause chronic lung
infections (Folkesson et al., 2012; Sousa & Pereira, 2014). Once a chronic infection is
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established cells that carry mutations that enable them to produce biofilms are selected due to the
exposure to harsh environment. Among the products produced in the biofilms is an
exopolysaccharide alginate (Schurr, 2013). Alginate is used by P. aeruginosa as a barrier to
protect the cells from the immune response and the used antimicrobials.
Alginate is regulated by a main sigma factor AlgU (σ22) that is sequestered to the inner
membrane by an anti-sigma factor MucA (Martinez-Salazar et al., 1996). MucA is a
transmembrane protein that has a periplasmic domain that is protected by MucB (C-terminus), an
intermembrane region, and a cytoplasmic region that sequesters AlgU (N-terminus) (Damron &
Goldberg, 2012). Mutations in MucA are the most common forms of selective mutations that
result in the conversion of the planktonic P. aeruginosa cells into alginate producing mucoid
cells. Mutations, such as the one found in the reference strain PDO300 known as MucA22
(G426*), results in a truncated MucA of 146 amino acids versus the 194 wt. protein and allows
for a lower affinity for AlgU and thereby a mucoid phenotype (Fig. 13).

mucA

421

GAGCAGGGGGCGCCGCAGGTGATCACCAACTCCTCGTCCAGCGATACCCGCTGGCATGAG

480

||||| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
mucA22

421

GAGCA-GGGGCGCCGCAGGTGATCACCAACTCCTCGTCCAGCGATACCCGCTGGCATGAG

479

MucA

110

ALPQMAQQGTTPQIALPQVKGPAVLAGYSEEQGAPQVITNSSSSDTRWHEQRLPIYLRQH

170

MucA22

110

ALPQMAQQGTTPQIALPQVKGPAVLAGYSEEQGRRR*

146

Figure 13. Comparison of mucA and mucA22 and the resulting proteins produced.
Nucleotide sequences of mucA compared to mucA22 showing the nonsense mutations G426*
(top). Amino Acid sequence of MucA compared to those of MucA22 showing the truncated
proteins that resulted from the nonsense mutations resulting in a 146 aa protein compared to the
194 wt. (bottom).
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Regulated intramembrane proteolysis (RIP) of MucA is a highly regulated process by
which protease cleave various sections of MucA in order to release AlgU into the cytoplasm
(Damron & Goldberg, 2012). The first protease is AlgW. AlgW is found in the periplasm of P.
aeruginosa and works on cleaving the C-terminus of MucA (D. Qiu et al., 2007). The second
protease to cleave MucA is MucP that is found in the transmembrane space (D. Qiu et al., 2007;
Wood & Ohman, 2009). The last part of the RIP cascade is a set of proteases known as
ClpXP/P2. These proteases are found in the cytoplasm of P. aeruginosa and cleave the
remaining N-terminus of MucA, thereby freeing AlgU (D. Qiu et al., 2008). Once AlgU is no
longer sequestered by MucA it activates the promoters of the algU operon as well as of the
biosynthetic operon, and thereby resulting in a mucoid phenotype (Yuta Okkotsu, 2013).
In this study, we showed that the overexpression of RIP proteases in PAO1 and PDO300
does not affect the mucoidy phenotype in PDO300 and is not induced in PAO1. Furthermore, we
show that loss of AlgW function results in an increase in proteolysis of MucA22, suggesting
increased activity of MucP cutting. Lastly, we show that mucA can be tagged on the chromosome
with HA to aid in studying in-vitro physiological levels of MucA and better understand its
proteolytic degradation under these conditions.
Results
Overexpression of the proteases AlgW, MucP, ClpP.
It is known that the three proteases AlgW, MucP, and ClpXP cleave MucA and release
AlgU, but it is not known whether overexpression of these genes for the enzymes in PAO1
would cause its conversion into mucoidy. Oppositely, it is not known whether overexpression of
these genes would disrupt the RIP cascade balance and result in a non-mucoid phenotype in an
otherwise mucoid strain such as PDO300. We overexpressed the genes using an expression
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vector that carries a pBAD promoter, pHERD20T, using 0.1% arabinose on PIA plates grown at
37 °C for 24 h (Fig. 14). The overexpression of the genes did not affect the mucoidy in PDO300
nor did it convert PAO1 into a mucoid strain. Therefore, an overabundance of the enzymes alone
would not result in altered proteolysis of MucA.

Figure 14. Overexpression of algW, mucP, clpP in PAO1 and PDO300 does not affect
mucoid phenotype.
Images showing PAO1 and PDO300 carrying the expression vector pHERD20T with the
protease genes algW, mucP, and clpP on PIA plates with carbenicillin (left) and with
carbenicillin plus 0.1 % of Arabinose (right) grown at 37 °C for 24 h.

Degradation of MucA22 by the proteases AlgW, MucP, ClpXP.
We know that MucA is degraded by various proteases, yet the proteolysis of MucA22 is
not well understood. The role of AlgW in cleaving MucA22 is not fully known. To map the
degradation of MucA22 by the various known proteases and to compare that to the degradation
of MucA, we overexpressed both mucA and mucA22 using the expression vector pHERD20T in
different strains of PAO1 with transposon insertions in algW, mucP, and clpXP (Fig. 15). In the
strain carrying the transposon insertion in algW, we saw an increase in the 16 kDa portion of the
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protein for MucA by western blot analysis, but a decrease of that same portion for MucA22 as
compared to PAO1. For MucA22 the 12 kDa band showed an increase in concentration between
PAO1 and PAO1algW (Fig. 15). These results suggest that under the absence of cutting by
AlgW, MucA22 is cleaved at a higher rate by MucP which results in a diminishing of the
intramembrane portion of the protein (16 kDa band) and an accumulation of the cytoplasmic
portion of MucA22 (12 kDa band).

Figure 15. MucA degradation in PAO1 and PAO1 with mutations at algW, mucP, and clpP.
Western blot showing the proteolytic degradation pattern of MucA and MucA22 by AlgW,
MucP, and ClpP. Lanes: 1- PAO1 + pHERD20T-HA-mucA, 2- PAO1algW + pHERD20T-HAmucA, 3-PAO1 + pHERD20T-HA-mucA22, 4- PAO1algW + pHERD20T-HA-mucA22, 5PAO1mucP + pHERD20T-HA-mucA, 6- PAO1mucP + pHERD20T-HA-mucA22, 7- PAO1clpP
+ pHERD20T-HA-mucA,8- PAO1clpX + pHERD20T-HA-mucA, 9- PAO1clpP + pHERD20THA-mucA22, 10- PAO1clpX + pHERD20T-HA-mucA22.

Chromosomal insertion of HA-tag to 5’ end of mucA and mucA22 in PAO1.
Investigation of MucA cleavage utilizes an expression vector carrying a tagged mucA
gene that allows for western blot testing to further understand and map this proteolysis. This
method relies on overexpression of the gene and thereby an overproduction of the protein,
conditions that do not resemble true physiological conditions and concentrations. To investigate
the in vivo degradation of MucA, mucA was chromosomally tagged with an influenza virus
hemagglutinin (HA) epitope of 9 amino acid residues (YPYDVPDYA) fused at the 5’-end of the
gene. This work would result in a MucA protein with an N-terminal HA-tag that would allow us
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to study the MucA degradation by RIP at physiological concentrations. Two variants of mucA
(wt. and mucA22) were fused to the Pseudomonas suicide vector pEX100T-NotI. Using the twostep allelic exchange and homologous recombination of overlapping DNA sequences, we were
able to produce a PAO1 strain with an HA-tagged mucA and mucA22, PAO1-HA-mucA and
PAO1-HA-mucA22, through simultaneously deleting the mucA gene and replacing it with the
tagged mucA/mucA22 genes carried by the pEX100T vector. These strains were compared to
PAO1 and PDO300 (Fig. 16) and PAO1-HA-mucA was still non-mucoid similarly to PAO1,
whereas PAO1-HA-mucA22 became mucoid similarly to PDO300. Alginate overproduction was
measured in both HA-tagged strains and compared to PAO1 and PDO300 (Fig. 17). When
comparing PAO1 and PDO300 alginate outputs to those of PAO1-HA-mucA and PAO1-HAmucA22 respectively, no differences were observed in alginate production using an anti-alginate
ELISA. This work shows that the produced strains indeed carry the HA-tagged mucA and
mucA22 genes that would enable studying the proteolysis of MucA under normal intracellular
concentrations.
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Figure 16. Comparing PAO1 and PDO300 to the PAO1-HA-mucA and PAO1-HA-mucA22
chromosomal constructs.
Plates of PAO1, PAO1-HA-mucA (left) and PDO300, PAO1-HA-mucA22 (right) grown on PIA
at 37 °C for 24 h.
A lg in a te A s s a y
100

A lg in a te C o n c e n tra tio n (  g /O D 6 0 0 )

ns

80

60

40

ns
20

0

PAO1

P A O 1 -H A - m u c A

PDO300

P A O 1 -H A - m u c A 2 2

Figure 17. Comparing the alginate production of PAO1 and PDO300 to the HA-muA and
HA-mucA22 chromosomal constructs.
Alginate assay using ELISA with an anti-alginate monoclonal antibody showing the alginate
concentration (μg/OD600) of PAO1, PAO1-HA-mucA, PDO300, PAO1-HA-mucA22. The
values represented are of mean alginate measured in triplicates with ± SE. The student t-test was
used to compare the mean concentration of alginate with p<0.01 (ns- no statistical significance).
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Discussion
The anti-sigma factor MucA sequesters AlgU and controls its ability to activate the
promoters for both the algU operon and the biosynthetic operon. Regulated proteolysis and the
degradation of MucA is a critical step in controlling the ability of P. aeruginosa to produce
alginate. MucA22 (146 aa) is a truncated protein that is 48 amino acids shorter than the wild type
protein (196 aa) at the C-terminus, periplasmic region. This truncation is critical for the RIP
enzymes to be able to have a higher degradation rate of MucA22 as compared to MucA resulting
in a mucoid phenotype. Since the mucA22 mutation is a prevalent mutation observed in many CF
isolates, it is important to understand how it is degraded and how this degradation results in the
mucoid phenotype in P. aeruginosa.
Our work showed that the overexpression of the RIP enzymes in PAO1 does not alter its
mucoidy phenotype and that it remains non-mucoid. Similarly, overexpression of the enzymes in
PDO300 (mucA22) does not inhibit the production of alginate by this strain. This observation
shows that a higher abundance of the various proteolytic enzymes, alone, is not enough to alter
the degradation pattern of MucA or MucA22. The enzymes are interlinked and likely degrade
MucA/MucA22 sequentially in a cascade. Therefore, a bottleneck effect might occur when only
one of the enzymes is found at a higher concentration while the two others are still at normal
concentrations. AlgW would be the first enzyme to cut the periplasmic section of MucA,
followed by MucP in the intramembrane, and lastly ClpXP would cut the remaining cytoplasmic
section (D. Qiu et al., 2008). Signals for each enzyme to initiate cutting might be a result of a
conformational change in the 3-D structure of the protein after losing the cut section, and this
conformational change might aid in the higher affinity to the following enzyme to bind to MucA
and thereby continuing the cascade. Our work cannot prove this theory since we still observed
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degradation products of MucA and MucA22 in AlgW-deficient strains. The fact that MucA still
gets degraded might indicate that a fourth enzyme may be involved in the proteolysis cascade
and would be replacing AlgW’s function. This enzyme may be Prc, the enzyme responsible for
degradation of mutant MucA (Reiling et al., 2005), or a yet to be discovered new enzyme.
Moreover, our findings indicated that, in PAO1algW, the cutting of MucA22 resulted in an
accumulation of the 12 kDa cytoplasmic portion of MucA22 and a decrease in the 16 kDa
intramembrane section. These findings suggest that, under deficient AlgW cutting, MucP might
be overactivated. This overactivity results in the degradation of MucA22 at a higher rate causing
the degradation of the intramembrane portion and accumulation of the cytoplasmic portion.
This work is an ongoing project and further experiments will be done to investigate the
complete degradation of MucA22 in P. aeruginosa. Future work will include the double
deletions of the protease genes of algW and mucP, algW and clpP, and algW and prc, to better
understand the degradation of MucA22. Since we saw a change in the degradation of the
intramembrane section (16 kDa band) of MucA22 under loss of function of AlgW, it is important
to identify the protease(s) responsible for this change. The section most likely corresponds to the
intramembrane cutting site of MucP; therefore, the protease MucP would be the likely candidate
of being over-active under loss of AlgW function. Yet, it is possible that Prc compensates for the
loss of AlgW cutting but results in an increase in the degradation of the intramembrane portion
of MucA22. Another possibility is that a new enzyme exists and that its function is either masked
or inhibited by AlgW proteolysis.
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Materials and Methods
Bacterial strains, plasmids, and growth conditions.
All bacterial strains used in this study are listed in Table 4. P. aeruginosa strains were all
grown on Pseudomonas Isolation Agar (PIA) plates (Difco, Detroit, MI) or Pseudomonas
Isolation Broth (PIB) (Difco, Detroit, MI) at 37 °C, prepared by adding 20 mL of glycerol/liter of
media as per manufacturer recommendation. PIA was supplemented with 300 μg/mL of
carbenicillin (RPI, Mt. Prospect, PA), 0.1%/ 0.5%/ 1% of arabinose (MP Biomedicals, Solon,
OH) by weight, 10% sucrose (Fisher Scientific, Waltham, MA) by weight when necessary. All
Escherichia coli strains were grown in Lennox Broth (LB) (Difco, Detroit, MI) or on LB agar
plates, and supplemented with 100 μg/mL of carbenicillin or 50 μg/mL of kanamycin (RPI, Mt.
Prospect, PA) when needed.
Bacterial Strain or plasmid
P. aeruginosa Strains
PAO1
PDO300
PAO1algW
PAO1mucP
PAO1clpP
PAO1clpX
E. coli Strains
TOP10
Plasmids
pRK2013
pHERD20T
pHERD20T-mucA
pHERD20T-mucA22
pEX100T-NotI
pEX100T-NotI-HA-mucA
pEX100T-NotI-HA-mucA22

Genotype, phenotype, or description

Source or reference

Prototroph, NM
Prototroph with mucA22 mutation, M
PAO1 algW::TetR, NM
PAO1 mucP::GmR, NM
PAO1 clpP::GmR, NM
PAO1 clpX::GmR, NM

P. Phibbs*
D. Ohman**
Washington University
(Qiu et al., 2008)
(Qiu et al., 2008)
(Qiu et al., 2008)

DH5α Derivative

Invitrogen

Kmr, Tra Mob ColE1
pUCP20T Plac replaced with 1.3-kb AflIII-EcoRI fragment of araC-PBAD
cassette
mucA (PA0763) from PAO1 in pHERD20T (pBAD/pUCP20),
EcoRI/HindIII
mucA22 (PA0763) from PDO300 in pHERD20T, EcoRI/HindIII
Suicide Vector with NotI restriction site fused into SmaI of pEX100T,
sacB, oriT, Cbr
400 bp fragment flanking mucA (PA0763) gene with 5’ HA-tag ligated
into pEX100T-NotI
400 bp fragment flanking mucA22 (PA0763) gene with 5’ HA-tag
ligated into pEX100T-NotI

(Figurski & Helinski, 1979)
(Dongru Qiu et al., 2008)
Genescript
Genescript
(Damron et al., 2009)
GeneScript
GeneScript

Table 4: Bacterial Strains and plasmids used in this study.
*P. Phibbs, East Carolina University, Greenville, NC.; **D. Ohman, Virginia Commonwealth
University, Richmond, VA; M=Mucoid; NM=Non-mucoid.
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Genomic DNA, Plasmid and Protein extractions.
Bacterial Genomic DNA was extracted using the DNeasy Blood and Tissue kit (Qiagen,
Germantown, MD) from 1x109 CFU/mL of cells grown in PIB or LB broth at 37 °C for 24 h.
Plasmids were extracted using the QIAprep Spin MiniPrep Kit (Qiagen, Germantown, MD) from
1x10^8 CFU/mL of cells grown in LB containing the necessary selective antibiotics at 37 °C for
24 h. Whole cell proteins were extracted using the NoviPure Microbial Protein Kit (Mo Bio,
Carlsbad, CA /Qiagen, Germantown, MD). Cells were grown on PIA plates containing the
necessary selection media supplement. Plates were scraped into 1x phosphate buffered saline
(PBS) and 1x108 CFU/mL of cells were pelleted and used to extract the whole cell protein using
the protocol provided with the kit. Protein concentration was measured using the BCA protein
assay kit (Thermo Fisher Scientific, Waltham, MA) and the optical density (OD) read on the
SpectraMax i3x (Molecular Devices, Downingtown, PA) at 562nm. All extracted samples were
stored at -20 ° C.
Conjugation.
Pseudomonas strains and the plasmid containing E. coli were grown in LB broth at 37 °C
for 24 h then 500 μL of each of the three strains (donor strain containing the plasmid, E. coli +
pRK2013, and recipient strain) were mixed in a 1.7 mL sterile elution tube. The mixture was
pelleted, and then was blotted on an LB plate and placed in the incubator face down at 37 °C for
4 h. The blot was streaked using an inoculating loop on PIA plates containing selective
antibiotics (carbenicillin 300 μg/mL with/without gentamicin 150 μg/mL depending on the
strain) and let incubate at 37 °C for 24 h. Single colonies were selected from the PIA plate and
isolated on selective PIA plates twice to obtain single colony isolates.
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In-Frame Gene Replacement.
Using the suicide vector pEX100TNotI carrying mucA wt. and mucA22 tagged with the
hemagglutinin epitope (HA), we made a chromosomal construct of PAO1-HA-mucA and PAO1HA-mucA22 using the two-step allelic exchange procedure. Single-crossover merodiploid strains
were selected based on sensitivity to sucrose (sacB) and resistance to carbenicillin. Selected
merodiploid strains where then grown in LB broth at 37 °C. Double-cross over strains were
selected based on sensitivity to carbenicillin and confirmed through PCR amplification of the
flanking region of the target gene.
Anti-Alginate ELISA.
An indirect ELISA using an Anti-Alginate Mouse Monoclonal Antibody (QED
BioSciences Inc. /Lot: 15725) was performed to measure the concentration of alginate. After 24
h incubation at 37 °C, alginate was harvested into 1x PBS and used to coat non-treated 96 well
plates (Costar). Primary and secondary (Anti-Mouse) antibodies added (1:2000 each) and
horseradish peroxidase activity detected using TMB, and reaction stopped using 2 N sulfuric
acid. The colorimetric reaction was measured at an OD of 450 nm using a Spectramax i3x plate
reader.
Western Blotting.
Western blots electrophoresis was performed using 4-20% TGX mini-plates (BioRad).
Using iBlot (Invitrogen), proteins were transferred onto a nitrocellulose membrane. Proteins
were detected using iBind (Invitrogen), primary anti-HA antibody -1:500 (R&D Biosystems) and
anti-rabbit antibody- 1:1500 (ThermoFisher) were bound to the membrane. Chemiluminescence
was detected using Amersham™ ECL Detection reagents (GE Healthcare) and FluoroChem
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(Protein Simple). The anti-α-subunit of RNA polymerase antibody was used as a control for
loading volumes.
Statistical Analysis.
The unpaired two-tail student t test was run with statistical significance set at p<0.01. All
statistical analysis was done using GraphPad Prism version 7.02 for Windows (GraphPad
Software).
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Abstract
Pseudomonas aeruginosa is a Gram-negative opportunistic bacterial pathogen that can
cause chronic lung infections in patients with cystic fibrosis (CF). The current preferred
treatments for CF lung infections include inhaled tobramycin (TOB); however, studies suggest
TOB cannot effectively inhibit biofilm formation. Using a NIH small compounds drug library
approved for safe use in humans, we identified rifaximin (RFX), a semisynthetic member of the
rifamycin family, non-systemic antibiotic that inhibits alginate production and growth in P.
aeruginosa. Inhibition of alginate production was further analyzed using the uronic acid
carbazole assay and a promoter reporter assay by measuring the transcription levels of the
alginate biosynthetic operon. Compared to TOB, RFX significantly reduced alginate production
in reference strains and CF sputum isolates of P. aeruginosa. In addition, RFX showed a lower
range of minimum inhibitory concentrations when measured with multidrug-resistant bacterial
species of clinical relevance. Moreover, RFX had synergistic activities with TOB or amikacin
against clinical isolates, as well as reduction towards in vitro pre-formed biofilms. C57BL/6
mice nebulized with RFX or TOB, showed higher penetration of TOB into the lungs compared to
RFX. Furthermore, in vivo assessment using a DBA/2 mouse lung-infection model found
decreased P. aeruginosa PAO1 bio-burden and increased survival rates with a single- or
multiple-dose treatment of nebulized RFX compared to TOB. In addition, mice treated with
nebulized dimethyl sulfoxide (DMSO), either alone or with RFX, showed no apparent toxicity
associated with either DMSO or RFX. In the final analysis, nebulized RFX decreased morbidity
from P. aeruginosa pneumonia in mice.
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Introduction
P. aeruginosa is an opportunistic bacterial pathogen responsible for hospital-acquired
infections and ventilator-associated pneumonia (Aloush, Navon-Venezia, Seigman-Igra, Cabili,
& Carmeli, 2006). The primary cause of mortality in patients with cystic fibrosis (CF) is a
consequence of chronic respiratory infections with P. aeruginosa (Boucher, Yu, Mudd, &
Deretic, 1997). Factors, such as biofilm formation and multidrug resistance, make P. aeruginosa
particularly difficult to treat (Nasirmoghadas et al., 2018).
Biofilms are formed when colonies aggregate and produce an extracellular matrix that
provides protection from antibiotics and immune responses (Head & Yu, 2004). P. aeruginosa
produces a matrix which contains a polysaccharide called alginate, which consists of a linear copolymer of guluronic and mannuronic acid (Head & Yu, 2004). The formation of P. aeruginosa
biofilms causes a poor prognosis in patients by decreasing lung function, and increased
morbidity and mortality (Ciofu, Tolker-Nielsen, Jensen, Wang, & Hoiby, 2015). The phenotype
of alginate overproduction by P. aeruginosa is also known as mucoidy and is a prevalent
phenotype in CF sputum isolates (Yu, Hanes, Chrisp, Boucher, & Deretic, 1998).
The current treatment strategy for CF patients with chronic P. aeruginosa infections is
daily administration of inhaled tobramycin for a period of 4 weeks. Tobramycin has been
formulated for the inhalational therapy (TOBI™). TOB is an aminoglycoside antibiotic with
broad spectrum activity against Gram-negative bacteria, including P. aeruginosa (Anderson,
Moreau-Marquis, Stanton, & O'Toole, 2008); however, studies have suggested that TOB alone
may not be an optimal treatment for CF chronic lung infections with P. aeruginosa, especially
biofilm producing strains. In vitro studies have shown that diffusion of TOB is inhibited to some
extent by the binding of TOB to alginate (Nichols, Dorrington, Slack, & Walmsley, 1988).
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Furthermore, the penetration of TOB through alginate biofilms and CF sputa is decreased,
especially at lower concentrations (Hoffman et al., 2005). Additionally, the use of multiple doses
of TOB therapy resulted in a decrease in P. aeruginosa strains’ susceptibility to aminoglycosides
due to the increase in drug impermeability (Hoffman et al., 2005; MacLeod et al., 2000). These
studies suggest that the addition of anti-biofilm agent may increase efficacy of nebulized
tobramycin in CF patients.
Rifaximin (Xifaxan™) is a broad-spectrum RNA polymerase inhibitor commonly used to
treat traveler’s diarrhea and hepatic encephalopathy (Iorio, Malik, & Schey, 2015; K. Mullen &
Prakash, 2010; K. D. Mullen et al., 2014). Rifaximin (RFX) is not water soluble and can be
delivered orally into the gastrointestinal tract in high dosages with little risk of uptake and
absorption into the body. Furthermore, RFX shows activity against P. aeruginosa and blocks
alginate production (Brown, Xue, Jiang, Xu, & Dupont, 2010; Ricci, Coppo, Barbieri, Debbia, &
Marchese, 2017).
In this study, we screened a NIH drug library of pharmaceutical active compounds
(Rothstein et al., 2005; Stavrovskaya et al., 2004) and identified RFX as a possible candidate to
treat P. aeruginosa lung infections. It was also determined that RFX was effective for treating
the multi-drug resistant P. aeruginosa isolates from CF patients. RFX was shown to be
significantly better at inhibiting alginate production in P. aeruginosa than TOB and that the
addition of RFX to TOB helped decrease already formed biofilms. Moreover, RFX could be
delivered to the lungs via nebulization and suppressed the P. aeruginosa infections in a
pneumonia mouse model. These results suggest that RFX may be a positive addition to TOB in
treating P. aeruginosa respiratory infections.
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Results
Screen of NIH drug library for inhibition of alginate production by P. aeruginosa
identified RFX.
Treatment with TOB cannot completely eradicate P. aeruginosa lung infections in CF, as
shown by various recent studies (Anderson et al., 2008; Cao et al., 2016; Ciofu et al., 2015;
Hoffman et al., 2005; Long et al., 2016; MacLeod et al., 2000). To identify an alternative
treatment strategy, a NIH drug library (Rothstein et al., 2005; Stavrovskaya et al., 2004) was
screened consisting of the 1,171 pharmacologically active compounds currently used in
pharmaceuticals and/or clinical trials, for inhibition of alginate production, as well as growth
inhibition activity against P. aeruginosa. Testing was performed at three concentrations of drugs
(50, 10 and 2 μM). A reporter plasmid containing the promoters for the alginate biosynthetic
operon (PalgD) attached to the lacZ operon was introduced into a stable mucoid laboratory strain
of P. aeruginosa PAO581 (Withers et al., 2013). Using this construct, growth and mucoidy
inhibition were measured, as well as alginate biosynthetic promoter activities. Fifteen drugs were
identified as inhibitors of mucoidy of P. aeruginosa (Table 5 and Fig. 18). These drugs were
further evaluated using a clinical mucoid isolate from a CF patient and it was concluded that
RFX was the most effective drug to inhibit growth and mucoidy of the tested isolate (data not
shown).
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Mucoidy

Growth

Color

50µM

10µM

2µM

50µM

10µM

2µM

50µM

10µM

2µM

Pazufloxacin

N/A

N/A

N/A

Inhibited

Inhibited

Inhibited

N/A

N/A

N/A

Moxifloxacin
Hydrochloride
Rifabutin

N/A

N/A

Reduced

Inhibited

Inhibited

Reduced

N/A

N/A

N/A

N/A

High

Inhibited

Inhibited

Reduced

N/A

N/A

Pefloxacin Mesylate

N/A

N/A

Inhibited

Inhibited

Inhibited

Reduced

N/A

N/A

Levofloxacin

N/A

N/A

N/A

Inhibited

Inhibited

Inhibited

N/A

N/A

Light
Blue
Light
Blue
Light
Blue
N/A

Carmofur

Inhibited Inhibited High

Reduced

Reduced

Yes

Clear

Clear

Tosufloxacin Tosilate

N/A

N/A

N/A

Inhibited

Inhibited

Inhibited

N/A

N/A

Light
Blue
N/A

Clarithromycin

Inhibited High

High

Yes

Reduced

Yes

Blue

Blue

Nisoldipine

Inhibited High

No Test

Yes

Yes

No Test

Blue

No Test

Rufloxacin Monohydrate

Inhibited High

No Test

Yes

Yes

No Test

Blue

No Test

Enrofloxacin

N/A

N/A

N/A

Inhibited

Inhibited

Inhibited

Light
Blue
Light
Blue
Light
Blue
N/A

N/A

N/A

Rifapentine

N/A

Reduced

High

Inhibited

Reduced

Yes

N/A

Blue

Rifaximin

N/A

N/A

Reduced Inhibited Inhibited Reduced N/A

Light
Blue
N/A

5-Nonyloxyltryptamine

High

High

No Test

Reduced

Yes

No Test

Blue

Blue

No Test

Unidentified

High

High

No Test

Reduced

Yes

No Test

Blue

Blue

No Test

Table 5. NIH Drug Library Small Molecule Tested for Alginate Inhibition.
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Clear

Figure 18. RFX results in loss of transcriptional activation of alginate biosynthetic operon
in a stable mucoid P. aeruginosa PAO581 carrying PalgD-lacZ.
Image showing a 24 well plate containing drugs (Table S1) and PAO581 carrying
pLP170_PalgD_lacZ construct grown at 37 °C for 24 h. Well C3 (in box) containing RFX shows
lack of blue colored colonies indicating the inhibition of β-galactosidase breakdown, suggesting
the PalgD promoter was inhibited by RFX.

RFX is effective against clinical isolates of Gram-negative and –positive bacteria
and has a synergic activity with TOB or amikacin.
Because RFX is not a traditional treatment for P. aeruginosa infections, we first wanted
to test whether it was effective in vitro against P. aeruginosa and other bacterial pathogens seen
in CF. Since RFX is not used for treatment of ventilator-associated pneumonia (Schaber et al.,
2004), we thought the isolates of tracheal aspirates from VAP patients in the ICU may be
sensitive to RFX. To determine the susceptibility to RFX, the minimum inhibitory concentrations
(MIC) were determined (Isenberg & American Society for Microbiology, 2004) for RFX against
a panel of clinical isolates from Cabell Huntington Hospital (Table 6). The MIC50 and MIC90 for
multidrug resistant (MDR) Staphylococcus aureus including methicillin-resistant S. aureus
(MRSA) was determined to be 2 and 16 µg/mL, respectively (Table 7). The MIC50 and MIC90
for MDR P. aeruginosa was determined to be 8 and 16 µg/mL, respectively (Table 7). The MICs
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of RFX were also determined for other drug-resistant pathogens that were associated with CF
and VAP. We found RFX can effectively inhibit the growth of clinical isolates of Burkholderia
cepacia, Acinetobacter baumannii and Stenotrophomonas maltophilia at a MIC90 range of <0.5
to 32 μg/mL (Table 7).
RFX is a member of the rifamycin family of antibiotics. Its function is to inhibit the
transcription by bacterial RNA polymerase; however, the mutations in the gene encoding the
bacterial RNA polymerase frequently emerge. To increase the efficacy of this group of
antibiotics, we considered whether RFX can be used in combination with antipseudomonal
antibiotics to reduce the frequency of resistant mutations of Pseudomonas. Checkerboard
(isoboloGram) analysis, testing for drug synergy between RFX and TOB combinations, showed
synergistic (ΣFIC ≤ 0.5) or additive (ΣFIC 0.5 < to ≤ 1) effects (Moody, 1992) in all the strains
tested (Table 8). In the final analysis, RFX was found to be a good candidate for further study as
an antibiotic adjuvant for the treatment of respiratory infections due to MDR pathogens.
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Clinical Bacterial Isolates
P. aeruginosa Isolates

Genotype, phenotype, or resistance profile

Source

K3050830
K3061403
K4040932
K4130630
K4111803
K5070734
K6150790a
K6150790b
K5180948
K5211493
K5230948
K5311090
K6150501
K7021701a
K7021701b
K7041915b
K8040645b
K8061883b
K8061883c
K8081410a
0232
0241
0242
0246
0248
0265

Sputum Sample: Cipro, Gent, Levo, Mero, Tobra
Sputum Sample: Aztre, Cefta, Cipro, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Amik, Aztre, Gent, Levo
Sputum Sample: Aztre, Cefta, Cefo, Pip
Sputum Sample: Aztre, Cefta, Cipro, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Cefta, Cefe, Pip
Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Cipro, Levo, Mero
Sputum Sample: Aztre, Cipro, Levo, Mero
Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Cipro, Levo
Sputum Sample: Aztre, Cipro, Tobra, Gent, Levo, Mero
Sputum Sample: Aztre, Cefta, Cipro, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Levo, Mero
Sputum Sample: Cipro, Levo
Sputum Sample: Amik, Gent
Sputum Sample: Aztre, Cefta
aadA6, OXA-50, PAO, strA, strB, sul1, tet(C)
aac (6')-IIc, aadA7, catB7, IMP-1, OXA-101, OXA-50, OXA-9, PAO, sul1
aac (3)-Id, aadA2, cmlA1, dfrB5, OXA-4, OXA-50, PAO, VIM-2
aadB, NDM-1, OXA-10, OXA-50, PAO, rmtD2, tet(G)tim, VEB-1
aac (3)-Id, aadA2, cmlA1, dfrB5, OXA-4, OXA-50, PAO, tet(G), VIM-2
aadB, catB7, OXA-50, PAO

CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CDCb
CDCb
CDCb
CDCb
CDCb
CDCb

Sputum Sample: Amp, Amox, Clinda, Cipro, Eryth, Levo, Meth, Oxa, Pen, Trim
Sputum Sample: Amp, Amox, Clinda, Cipro, Eryth, Levo, Oxa, Pen
Sputum Sample: Amp, Amox, Cipro, Eryth, Levo, Meth, Oxa, Pen
Sputum Sample: Amp, Amo, Clinda, Cipro, Eryth, Levo, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Cipro, Eryth, Levo, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Cipro, Eryth, Levo, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Cipro, Eryth, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Cipro, Eryth, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Eryth, Meth, Oxa, Pen
Brochial Wash: Amp, Amox, Clinda, Cipro, Eryth, Levo, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Clinda, Cipro, Eryth, Levo, Meth, Oxa, Pen

CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa

S. aureus Isolates
K3030365
K3051765
K3171696
K3171648
K3211227
K3251277
K3270906
K3300507
K4010571
K5090899
K5091554

71

Clinical Bacterial Isolates

Genotype, phenotype, or resistance profile

Source

K5121709
K5150830
K5160682
K5160792
K5180796
K5221462
K5240801
K5281689
K5282054
JE2 parent
COL

Tracheal Aspirate: Amp, Amox, Clinda, Cipro, Eryth, Levo, Meth, Oxa, Pen
Sputum Sample: Amp, Clinda, Eryth, Pen
Sputum Sample: Amp, Pen
Sputum Sample: Amp, Amo, Clin, Eryth, Meth, Oxa, Pen
Sputum Sample: Amp, Amox, Clinda, Cipro, Eryth, Levo, Meth, Oxa, Pen, Trim, Tet
Sputum Sample: Clinda, Eryth, Gent, Tet
Sputum Sample: Susceptible
Sputum Sample: Amp, Amox, Clinda, Cipro, Eryth, Meth, Oxa
Sputum Sample: Amp, Amo, Eryth, Meth, Oxa, Pen
mecA, SCCmec IVa, USA 300, pvl+
mecA, SCCmec I

CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
NARSAc
NARSAc

Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Cipro, Levo
Sputum Sample: Aztre, Cipro, Tobra, Gent, Levo, Mero
Sputum Sample: Aztre, Cefta, Cipro, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Cefta, Cipro, Cefe, Tobra, Gent, Levo, Mero, Pip
Sputum Sample: Aztre, Levo, Mero
Sputum Sample: Cipro, Levo
Sputum Sample: Amik, Gent
Sputum Sample: Aztre, Cefta

CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa
CHHa

LMG 18941, ATCC BAA-246
UCB 717, ATCC 25416

NIHd
NIHd

A. baumannii Isolates
K5311090
K6150501
K7021701a
K7021701b
K7041915b
K8040645b
K8061883b
K8061883c
K8081410a

B. cepacia Isolates
BC702
BC707

Table 6. Clinical isolates used for MIC testing.
a
Cabell Huntington Hospital Patient Samples, Huntington, WV, bCDC Antimicrobial Resistance Isolate Bank, cNetwork on
Antimicrobial Resistance in Staphylococcus aureus (NARSA), dNIH Biodefense and Emerging Infections Research Resources
Repository
*All none ATCC strains used for MIC work listed above.
Amik= Amikacin; Amox= Amoxicillin; Amp= Ampicillin; Aztreo= Aztreonam; Cefta= Ceftazidime; Cefe= Cefepime; Cipro=
Ciprofloxacin; Clinda= Clindamycin; Eryth= Erythromycin; Gent= Gentamicin; Levo= Levofloxacin; Mero= Meropenem; Meth=
Methicillin; Oxa= Oxacillin; Pen= Penicillin; Pip= Piperacillin; Tob= TOB; Trim= Trimethoprim (Indicates Strain Resistance to
specified Antimicrobials)
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Bacterial species

# Strains tested

MIC50 (mg/L)

MIC90 (mg/L)

Pseudomonas aeruginosa

26

8

16

Staphylococcus aureus

22

2

16

Acinetobacter baumannii

9

< 0.5

< 0.5

Burkholderia cepacia

4

16

32

Stenotrophomonas maltophilia

1

16

16

Table 7. Determination of RFX MICs against clinical isolates of MDR bacterial species.
Sources of clinical isolates is listed in Table 7. MIC50 and MIC90 are the concentrations of RFX
required for the growth inhibition of 50% and 90% of strains, respectively.

FIC TOB

ΣFIC

Activity

0.125

0.375

++

0.5

0.25

0.5

+

2

0.5

0.25

0.5

+

0.25

2

0.5

0.25

0.5

+

2

0.25

2

0.5

0.25

0.5

+

1

0.25

2

0.25

0.125

0.375

+

Strain

Type

PAO1

NM

MIC
RFX
16

MIC RFX in FIC MIC MIC TOB in
Combination RFX TOB Combination
4
0.25
2
0.25

PAO581

M

16

4

0.25

2

PAO581

16

4

0.25

CF001

NM
revertant
M

16

4

CF010

M

8

CF003

NM

4

Table 8. Minimum inhibitory concentrations and synergy activity of RFX and TOB against
P. aeruginosa strains.
NM=Non-mucoid; M=Mucoid
‡ lowest ΣFIC measure: synergy (++) ≤ 0.5; additive (+) 0.5 < to ≤ 1; indifferent (±) 1< to ≤ 4;
antagonism (-) > 4 (Moody, 1992).
RFX is more effective than TOB in inhibiting the alginate production in P.
aeruginosa.
The results of the preliminary drug screening indicated that RFX may inhibit alginate
biosynthesis. To investigate the extent of this inhibition, we grew PAO1 (wild type non-mucoid
73

reference strain), PAO581 (PAO1mucA25- mucoid reference strain) and two mucoid P.
aeruginosa CF isolates (CF001 and CF010) (Al Ahmar et al., 2018) on PIA plates containing
sub-MIC concentrations of either TOB or RFX and measured alginate production with the
carbazole assay. We chose these isolates because they had a similar MIC range for RFX and
TOB and were still sensitive to TOB. We used the MIC normalization to compare the effect of
the two drugs on inhibition of alginate production, as this allows for the measurement of alginate
made by the same number of bacterial cells. Using this method, there was no observed
significant difference in alginate production by the non-mucoid strain PAO1 when treated with
TOB or RFX at any concentration (Fig. 19 A). Conversely, RFX significantly decreased alginate
production in the mucoid PAO581 strain at all concentrations tested, as compared to TOB in
mucoid strain PAO581 (Fig. 19 B). We further observed a significant decrease in alginate
production in the mucoid CF isolates CF001 and CF010 as compared to TOB (Fig. 19 C and D).
These results indicate that RFX is more effective than TOB at inhibiting the alginate production
in mucoid strains of P. aeruginosa.
While RFX inhibits alginate production, we wanted to determine whether the inhibition
was specific to alginate or whether it was a global suppression of transcription. To test this, we
used the promoter reporter constructs PalgD_lacZ in pLP170 (Withers et al., 2013) to quantify the
promoter activity of the alginate biosynthetic operon P algD. A promoter-less empty vector
pLP170-lacZ was used as a negative control. Using the β-galactosidase reporter activity, we
quantified the activity of PalgD in PAO581 (Fig. 20 A), and in two mucoid isolates (CF001 and
CF010) from CF patients. When grown in PIA containing various concentrations of RFX or
TOB (Fig. 20 B and C), RFX had a more pronounced effect on promoter induction activity than
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TOB throughout the entire concentration range in all three tested strains. Based on these data, it
was concluded that RFX inhibits alginate biosynthesis by antagonizing transcription.

Figure 19. RFX is more potent than TOB for inhibition of alginate production of
laboratory and CF sputum isolates of P. aeruginosa.
Alginate production for (A) non-mucoid reference strain PAO1, (B) PAO581 (PAO1mucA25),
and stable mucoid clinical isolates (C) CF001 and (D) CF010 when grown on PIA at 37 °C for
24 h with increasing concentrations of RFX or TOB according to the predetermined MIC. Data
shown represent means of 5 replicates per group ± SE. Two-way ANOVA analysis was used
with statistical significance set as p < 0.01. (**** p < 0.0001, ** p < 0.001, * p < 0.01).
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Figure 20. RFX vs TOB mediated inhibition of the promoter PalgD activity of the alginate
biosynthetic operon in laboratory and clinical isolates of P. aeruginosa.
The β-galactosidase activity of PalgD was measured using pLP170-PalgD-lacZ reporter
construct in (A) PAO581, (B) CF001, and (C) CF010 grown on PIA plates with increasing
concentrations of RFX or TOB (MIC1, MIC10, MIC30, MIC50) at 37 °C for 24 h. Relative
expression mean values are shown ± SE of triplicate determinations. Two-way ANOVA was
used to determine statistical significance set at p < 0.01 (**** p < 0.0001).
TOB in combination with RFX reduces the biofilm aggregates and viable cell
counts.
We determined that RFX inhibited alginate production. We, then, tested the ability of
RFX to reduce biofilm aggregates, defined as a decrease in preformed biofilm, as well as the
biofilm viable cell counts. An established biofilm reduction assay (Sheppard, McAleer, Saralkar,
Geldenhuys, & Long, 2018) and viable cell counts were performed using PAO1 and mucoid
clinical isolates CF001 and CF010. TOB significantly reduced biofilm as compared to the
untreated control (Fig. 21 A). TOB with the addition of RFX significantly reduced the biofilm
aggregates as compared to TOB alone. Furthermore, TOB significantly reduced the number of
viable cells in a preformed biofilm as compared to the untreated control. The addition of RFX
with TOB significantly reduced this number further, enhancing the efficacy of TOB alone (Fig.

76

21 B). This result provides evidence that the addition of RFX helps TOB penetrate biofilms and
decrease biofilm viable cell counts.
A.

B.

Figure 21. Biofilm and cell viability reduction from treatment with TOB and/or RFX.
(A) Plot showing the effect of TOB and/or RFX on the total biofilm aggregates in PAO1, CF001,
and CF010. Biofilms were grown for 24 h in 96 well plate then treated with TOB, RFX, or TOB
and RFX at concentration of 3x MIC and then stained with 0.1% crystal violet and absorbance
measured via OD at 595 nm. (B) Plot showing the effect of TOB and/or RFX on the total viable
cell counts in PAO1, CF001, and CF010. Biofilms were grown for 24 h in 96 well plate then
treated with TOB, RFX, or TOB and RFX at concentration of 3x MIC and then stained with
MTT and absorbance measured via OD at 570 nm. Two-way ANOVA analysis was used with
statistical significance set as p<0.01 (**** p < 0.0001, ** p < 0.001, * p < 0.01).
RFX can be delivered to the lungs via nebulization.
As treatment for traveler’s diarrhea, RFX is a drug optimized for oral use. For RFX to be
useful as a treatment for CF patients, we wanted to test whether it could be delivered to the lungs
through nebulization. The physiochemical properties make RFX only sparingly soluble in water,
therefore, DMSO was evaluated as a nebulization vehicle. The potential adverse effects were
first assessed by nebulizing DMSO alone to a group of C57BL/6 mice (n=8). We used this type
of mouse due to their natural resistance against infection based on our previous studies (Wilson,
Napper, Denvir, Sollars, & Yu, 2007). Exposure to a single dose of 5 mL of nebulized 100%
DMSO caused no adverse effects. One month after exposure, all exposed mice were alive with
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body weights comparable to the PBS-treated control mice (data not shown). Next, we optimized
the delivery of both RFX and TOB via nebulization. RFX or TOB was delivered to the lungs of
C57BL/6 mice (n=16) using a pressure-based nebulizer and whole-body exposure chamber with
targeted delivery concentrations of 100 mg or 400 mg per mouse lungs (weight estimated to be
200 mg per mouse lung). These two concentrations were chosen as the current approved clinical
treatment for nebulization therapy in human CF is 300 mg TOB nebulized in 5 mL of 0.225%
saline. Thus, both RFX and TOB were naturally respired by the mice. To determine the dosage
of each drug received by the mice, the lungs were homogenized and drug concentrations of TOB
and RFX were determined via ELISA and HPLC, respectively. RFX and TOB were present in
the lungs at similar concentrations after the 100 mg nebulization (Fig. 22); however, at 400 mg
nebulization, TOB exhibited a non-statistically significant increase in lung concentration over
RFX. These results indicate that nebulization can deliver both drugs to the mouse lung at a low
dose (100 mg), but TOB may penetrate the lung tissues more efficiently than RFX at a high dose
(400 mg). To determine variance of drug delivery caused by difference in solvents, particle size
analysis of the drug droplets was done using a Malvern Spraytec for both drugs. The droplet size
for both TOB and RFX were determined to be identical with the average droplet size for TOB
and RFX being 5.07 µm and 5.02 µm, respectively (Fig. 23).
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Figure 22. Comparison of the levels of RFX and TOB delivered via nebulization in mouse
lungs.
The concentration of RFX or TOB present in lungs of C57BL/6 mice immediately after
treatment with 100 or 400 mg of the respective antibiotics. Data shown represent means of 4
lung samples with replicates totaling 8 samples per group ± SE. One-way ANOVA was used to
analyze the data with statistical significance set at p<0.01. No differences were found between
the RFX vs TOB concentrations present in the mouse lungs.

Figure 23. Droplet Size comparison of nebulized TOB and RFX showed no difference in
particle size.
Overlay plots of (A) RFX and (B) TOB particle size comparisons showing stable and consistent
droplet size over time when nebulized. Data produced using the Malvern Spraytec in triplicates.
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RFX effectively treats P. aeruginosa infection in mice.
After establishing the dosing of TOB or RFX to efficiently reach the lungs, we compared
the efficacy of both drugs against P. aeruginosa lung infections using an established mouse
model (Wilson et al., 2007). DBA/2 (n=84) male mice were first infected with aerosolized P.
aeruginosa PAO1 in a whole-body exposure chamber as previously described (Yu & Head,
2002). The mice were then separated into four groups. One group was left untreated to determine
the rate of mortality (control). The remaining three groups were treated with RFX or TOB using
a pressure-based nebulizer and whole-body exposure chamber at a concentration of 300 mg at 0
h, 6 h, or 12 h post infection. All control mice died within 5 days (Fig. 24), consistent with what
was previously reported (Wilson et al., 2007). Treatment with RFX or TOB at 0 h after infection
resulted in 100% and 92% survival, respectively (Fig. 24 A). At 6 h post infection, treatment of
RFX resulted in 92% survival, while 58% of mice treated with TOB survived (Fig. 24 B). In the
12 h treatment group, 83% of mice treated with RFX survived, while only 50% of mice treated
with TOB survived (Fig. 24 C). Thus, RFX treatment after P. aeruginosa lung infection resulted
in a higher survival rate than TOB treatment in a mouse lung infection model.
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Figure 24. RFX is more effective than TOB in the treatment of P. aeruginosa infection in
mice.
Kaplan-Meier curves showing percent survival of DBA/2 mice with P. aeruginosa PAO1
infection after treatment with RFX or TOB (A) 0 h post infection, (B) 6 h post infection and (C)
12 h post infection. Data shown represent means of 12 mice per group. The Mantel-Cox test used
with significance set at p < 0.01 and showing the Standard Error (SE) bars.
The addition of RFX to multiple treatments of TOB reduces P. aeruginosa growth in
lungs of mice.
Based on the efficacy seen with the single dose treatment, we used a multiple dose study
to replicate clinical treatment conditions seen with CF infections. The efficacy of TOB in
multiple doses with or without RFX was determined using the established lung infection model.
DBA/2 (n=24) female mice were exposed to aerosolized P. aeruginosa PAO1 with a
chromosomal bioluminescent operon (luxCDABE) as previously described (Wilson et al., 2007).
A bioluminescent PAO1 was used to track the respiratory bacterial load as well as determine the
presence of the lung normal flora through monitoring bacterial bioluminescence on growth plates
from lung samples. The mice were then separated into three groups of 8: one group was
untreated. The second group received three separate TOB treatments of 60 mg/mL respectively
at 6 h, 8 h, and 10h post infection. The third group received an initial RFX treatment of 60
mg/mL at 6 h post infection followed by two TOB treatments of 60 mg/mL at 8 h and 10 h post
81

infection. The group without treatment had the highest amount of bacterial load with growth
increasing to a maximum of 109 CFUs at 24 h post infection (Fig. 25). Multiple treatments of
TOB reduced the amount of bacterial growth in the lungs and kept the growth steady at around
108 CFUs. With the addition of RFX to the doses of TOB, growth was further reduced and kept
consistent at 106 CFUs. All colonies isolated from the lung homogenates of the infected mice
were bioluminescent (Fig. 26) suggesting that the total bacterial load resulted from the initial
infection.

Figure 25. Addition of RFX to multiple treatments of TOB results in decrease of CFUs/mL
of P. aeruginosa in mouse lungs.
Plot showing the CFU/mL counts of mice after being infected with P. aeruginosa and left
untreated, treated with multiple doses of TOB, or treated with multiple doses of TOB with
addition of RFX. Data shown represent average of 2 mice per time point per group. Two-way
ANOVA was used to test for statistical significance with p < 0.01. (**** p < 0.0001).
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A.

B.

Figure 26. Comparison of lung bacterial loads using bioluminescence-labelled P.
aeruginosa PAO1.
LB plates of P. aeruginosa PAO1 with a bioluminescent marker from the mouse lung
homogenates after infection comparing (A) TOB treated group at 18 h post-infection at 10-5
dilution and (B) TOB+RFX treated group at 18 h post-infection at 10-5 dilution.
Discussion
Biofilm formation by P. aeruginosa is a major risk factor for people suffering CF (Hoiby,
Ciofu, & Bjarnsholt, 2010). Current treatment includes the repeated use of inhaled TOB. This
antibiotic may not continue to be an effective treatment strategy due to emerging aminoglycoside
resistance in P. aeruginosa due to the biofilm formation that results in decreased permeability of
TOB. In this study, we found that RFX, which has been approved for use in treatment of
traveler’s diarrhea, irritable bowel syndrome, and hepatic encephalopathy, has antibacterial
activity against P. aeruginosa and other MDR bacterial pathogens and can inhibit alginate
production. Furthermore, RFX was effective against other bacterial pathogens associated with
respiratory infections in CF and patients with VAP. These data suggest that RFX may be an
effective antibiotic adjuvant for respiratory infections in CF patients.
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Previous research has shown that the efficacy of TOB is hindered by its inability to
penetrate and inhibit biofilm production (Long et al., 2016). Although a biofilm is a general
description of the matrices produced by P. aeruginosa, and, has many components (Hoiby et al.,
2010), we used alginate production as a representation of biofilm production in this study.
Carbazole assays were performed using media containing either RFX or TOB to measure the
inhibitory effect on alginate production. In all mucoid strains tested, RFX significantly decreased
alginate production compared to TOB. This decrease in alginate production suggests that RFX
may inhibit alginate biofilm production and enhance bacterial uptake of TOB by P. aeruginosa
in CF patients.
Once determining the inhibition of alginate and decrease in biofilm production by TOB
and/or RFX, we investigated the reduction of preformed biofilms and viable cell counts with P.
aeruginosa strains PAO1, CF001, and CF010 to determine their efficacy. TOB alone
significantly reduced biofilm aggregates and viable cell counts compared to untreated samples.
However, TOB was more effective in combination with RFX, as both reduced biofilm
aggregates and viable cell counts compared to TOB alone. This result suggests that the addition
of RFX may be a positive component to treating biofilm producing strains of P. aeruginosa,
acting as an enhancer of TOB biofilm penetration. Thus, patients with complications from
biofilm producing species may benefit from the addition of RFX.
The unique physiochemical and pharmacokinetic (PK) properties compared to other
rifamycins further led us to focus on RFX for an in vivo study. Oral RFX has low solubility in
water and achieves high intestinal concentrations due to poor absorption. We found that RFX is
readily soluble in DMSO, which is a solvent that is used at low concentrations in chronic
obstructive pulmonary patients (COPD) to alleviate tar build up due to smoking (Kimura, Traber,
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Herndon, Neuhaus, & Traber, 1988). However, recent studies suggest DMSO to be toxic and
produce cellular apoptosis at low concentrations (2-4% by volume) (Galvao et al., 2014). To
examine possible toxicity associated with DMSO inhalation, mice were exposed to 100% DMSO
prior to testing the drugs, and no physical adverse effects (irritation, activity level, body weight,
or death) were observed. Delivery of nebulized RFX in DMSO and TOB in saline was next
compared in mice via inhalation in a whole-body exposure chamber. The nebulization exhibited
low efficiency. The concentrations of bacteria and drugs nebulized were significantly higher than
the amount delivered into the lungs, but this was expected as the system relies on delivery of
drugs via natural respiration. This method is used over intra-tracheal delivery to decrease or
eliminate the possibility of injury with the insertion of tracheal tubes that could be misinterpreted
as adverse effects of RFX, as well as the change in respiratory patterns while anesthetized.
Importantly, we optimized the inhalational delivery of drugs by measuring the tissue level of
drugs via HPLC and ELISA. At lower dosages (20 mg/mL of nebulized drug), both TOB and
RFX were delivered into the lung at a similar concentration; however, at higher concentrations of
nebulized drug (80 mg/mL of nebulized drug), TOB was delivered more efficiently to the mouse
lung compared to using RFX (Fig. 22). This result may be due to the low solubility and
absorption of RFX in the lung, but the cause is not known at this time. Droplet size analysis for
both drugs revealed the drugs to be identical ruling out any variance caused by differences in
particle size. No adverse effects were observed in the RFX treated mice. The mice behaved
normally and survived for several months after the nebulization until they were euthanized. In
summary, our data indicated that RFX can be delivered to the lungs via nebulization at
measurable levels. Future studies would focus on optimizing the drug delivery method and
determining the cause of the difference in concentration between the drugs at higher dosages.
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After determining that RFX was deliverable via inhalation, we tested for therapeutic
efficacy using a P. aeruginosa pneumonia model (Wilson et al., 2007). The ideal testing would
be the use of an animal model with chronic lung infection caused by mucoid strains of P.
aeruginosa to correlate the clinical condition of a CF patient; however, to date, no model has
been developed. Alternatively, we used an acute lung infection mouse model that was initiated
through natural respiration of P. aeruginosa aerosol in mice. We previously found that DBA/2
mice are highly susceptible to the lung colonization by P. aeruginosa in comparison to other
inbred mouse strains. Lung infections in DBA/2 mice with non-mucoid strains of P. aeruginosa
PAO1 resulted in excessive infiltration of neutrophils to the mouse lungs followed by massive
formation of edema (Wilson et al., 2007). The mice typically die within 120 h after lung
infection. In this study, this model was used to test the drug efficacy for treating P. aeruginosa
respiratory infections in mouse. Overall, more mice survived after treatment with RFX than all
other experimental groups (100%, 92%, and 84% survival after 0 h, 6 h and 12 h treatments
compared to 84%, 58%, and 50% survival for mice treated with TOB respectively). Although
multiple treatments are used in clinical settings, a single dose treatment was used in this study to
test the preliminary efficacy of TOB versus RFX. Future studies will focus on determining if
alginate production is inhibited in a chronic lung infection mouse model since the model used in
this study is that of an acute, non-biofilm producing, infection.
Once a single dose study determined the efficacy of TOB vs RFX, a multiple dose study
was used to determine the effect of adding RFX to multiple treatments of TOB, which would
correlate more with clinical treatment methods. The animal model for the multiple dose
experiment was identical, with the exception that the P. aeruginosa strain PAO1 used had a
stably expressed bioluminescent marker to help track the bacteria and to determine presence in a
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native microbiome. In this study, we observed that the addition of RFX reduced bacterial growth
compared to TOB alone. Bioluminescence was also conserved and seen in all colonies grown
from lung homogenates suggesting that no native bacteria were culturable. These results
strengthen the idea that the addition of RFX would aid TOB in penetration of P. aeruginosa
biofilm infections.
In conclusion, we have shown that RFX is a potential candidate to be used against known
lung pathogens as a supplementary additive to the currently established TOB treatment. RFX
was shown to efficiently reach the lungs and increase survival rates in P. aeruginosa lung
infections in mice. Since RFX is being repurposed for the use in the lungs, further testing is
required to better understand the pharmacokinetics and toxicity of RFX when delivered in the
lungs. In addition, further testing will be conducted to replace DMSO with a water-based solvent
for RFX to reduce possible adverse effects of DMSO.
Materials and Methods
Bacterial strains, plasmids, and growth conditions.
All bacterial strains used in this study are listed in Table 9. P. aeruginosa strains were all
grown on Pseudomonas Isolation Agar (PIA) plates (Difco, Detroit, MI) or Pseudomonas
Isolation Broth (PIB) (Difco, Detroit, MI) at 37 °C, prepared by adding 20 mL of glycerol/liter of
media as recommended by the manufacturer. PIA was supplemented with 300 μg/mL of
carbenicillin when necessary.
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Bacterial Strain or plasmid
P. aeruginosa Strains
PAO1
PAO581
CF001
CF003
CF010

Genotype, phenotype, or description

Source or reference

Prototroph, NM
PAO1 mucA25, M
CF Isolate, M
CF Isolate, NM
CF Isolate, M

P. Phibbs a
J. Govan b
M. Anstead c
M. Anstead c
(Head & Yu, 2004)

Plasmids
pRK2013

Kmr, Tra Mob ColE1

pLP170

8.3-kb, promoterless-lacZ, Apr, multiple cloning site

pLP170-PalgD

Complete PalgD promoter (989 bp upstream of ATG)
fused with lacZ in pLP170 BamHI/HindII
Pseudomonas suicide vector that carries luxCDABE
operon for insertion into attTn7 sites

(Figurski &
Helinski, 1979)
(Preston et al.,
1997)
(Ryan Withers et
al., 2013)
(Choi & Schweizer,
2006)

pUC18-mini-Tn7T-lux

Table 9: Bacterial Strains and plasmids used in this study.
a
P. Phibbs, East Carolina University, Greenville, NC, b J. Govan, University of Edinburgh,
Scotland, U.K., c M. Anstead, University of Kentucky Department of Pediatrics, Lexington, KY;
NM=Non-mucoid; M=Mucoid
Screen for drug candidates that inhibits growth and alginate production in P.
aeruginosa.
The drug collection library was assembled by the National Institutes of Health (NIH)
through the Molecular Libraries Roadmap Initiative. It is called NIH clinical collections 1 and 2
(NCC plates 105 and 106) and contains 446 and 725 compounds, respectively. The library was
arrayed in 96-well plates as an approximately 10 mM solution in 100% DMSO. These small
molecular weight compounds all have a history of safe use in human clinical trials and were
curated and supplied by Evotec. Three concentrations of drugs (50, 10 and 2 μM) were used to
screen for the inhibition of growth and alginate production in P. aeruginosa. A mucoid strain of
P. aeruginosa PAO581 (PAO1mucA25), was introduced with plasmid pLP170 carrying the
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alginate biosynthetic promoter PalgD fused with a promoterless lacZ operon. This strain was
grown with about the same number of cells as adjusted by optical density for the screen on
Pseudomonas isolation agar (PIA) supplemented with 5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside (X-gal) to a final concentration of 20 μg/mL.
Minimum inhibitory concentration testing.
MIC testing was performed as previously described (Isenberg & American Society for
Microbiology., 2004). Overnight culture of bacteria was diluted in 1:100 of a 0.5 McFarland
standard as inoculum. The same number of cells was grown in LB broth containing serial, twofold dilutions of RFX or TOB. Growth was measured via optical density (OD) at 600 nm after 24
h incubation at 37 °C. Concentrations of antibiotic required for inhibition of 50% and 90% of
strains were determined.
Synergy testing.
Synergistic potential of RFX and TOB was performed by isoboloGram (checkerboard)
analysis in 96-well plate format (Isenberg & American Society for Microbiology., 2004). Briefly,
PIB containing serial dilutions of each drug were plated in 64 wells of a 96-well plate with one
drug vertically plated and the other horizontally plated. Bacterial cells of P. aeruginosa were
grown 4 to 6 hours to an early log phase and then added to the wells of the plate. Growth in the
wells was measured via OD at 600 nm after 24 h incubation at 37 °C. The MIC and Fractional
Inhibition Concentration (FIC) were calculated to determine synergism, antagonism or additivity
between the tested strains of P. aeruginosa: PAO1, PAO581, PAO581 isogenic mutant, CF001,
and CF010. The summative ΣFIC was calculated from the FICs and interpreted according to the
standard index values: synergy ≤ 0.5; indifferent 0.5 < to ≤ 4; antagonism > 4 (Moody, 1992).
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Uronic acid carbazole assay.
Alginate production was measured via carbazole assay (Knutson & Jeanes, 1968).
Laboratory and clinical isolate strains were grown in PIB from a single colony isolation. The
strains were then plated on 150 mm agar plates containing no antibiotic; RFX at concentrations
of 10 µM (MIC50), 6 µM (MIC30), 2 µM (MIC10), and 0.2 µM (MIC1); or TOB at concentrations
of 2 µM (MIC50), 1.2 µM (MIC30), 0.4 µM (MIC10), and 0.04 µM (MIC1) and incubated at 37 °C
for 48 h. Sterile PBS (30 mL) was added to the plates and the cells plus their mucoid film were
collected into 50 mL conical tubes. A 1 mL sample was taken to measure growth via OD at 600
nm. A 700 µL sample was then added to tubes containing 6 mL of a sulfuric acid–borate
solution. A 200 µL aliquot of 0.1% carbazole was then added to the tubes and incubated for 30 m
at 55 °C. The alginate was then measured via OD at 530 nm and plotted against a standard curve
made with D-mannuronic acid (Sigma-Aldrich). The reported values represent an average from
three independent alginate collections with standard deviation.
Biofilm Reduction Assay.
A biofilm reduction assay developed by Sheppard et al. (Sheppard et al., 2018) was used
to determine the reduction of biofilms in P. aeruginosa strains by TOB and/or RFX. Briefly,
biofilms were grown in a flat bottom 96-well microplate (Corning) using 200 μL LB of 1.0-1.5 x
105 inoculum of lab and clinical strains of non-mucoid and mucoid P. aeruginosa. After 24-30 h
incubation at 37 °C, the media was removed, and plates were washed with PBS. New media
containing 1-5x MIC90 of TOB and/or RFX was added to the plate in a checkerboard pattern to
determine synergy of biofilm reduction. After 24 h incubation at 37 °C, the media was removed
and 200 μL of 0.1% aqueous crystal violet was added and left at room temperature for 30 min.
The solution was then removed, plates were washed with PBS, and 200 μL of 30% acetic acid
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was added. The plates were then read via OD at 595 nm using SpectraMax i3x plate reader to
compare biofilm dispersion between TOB and/or RFX.
Viable Cell Assay.
Viable cell counts were done to determine the reduction of viable cells in preformed
biofilms treated with TOB and/or RFX. Briefly, following biofilm reduction protocol, biofilms
were grown in a flat bottom 96-well microplate (Corning) using 200 μL LB of 1.0-1.5 x 105
inoculum of lab and clinical strains of non-mucoid and mucoid P. aeruginosa for 24 h at 37 °C.
After incubation, the media was removed, and plate was washed with PBS twice. New LB media
containing 1-5x MIC90 of TOB and/or RFX was added to the plate in a checkerboard pattern.
After 24 h growth at 37 °C, the media was removed and replaced with methyl thiazol tetrazolium
(MTT; Sigma). After 1 h incubation, DMSO was added and plates were read via OD at 570 nm
using SpectraMax i3x plate reader to determine viable cell differences between TOB and/or
RFX.
Mice.
Protocols for murine lung infections and in vivo drug efficacy testing were approved by
Marshall University Institutional Animal Care and Use Committee (IACUC). Animals used in
this study were obtained from Charles River Laboratories (Wilmington, MA). C57BL/6 mice
were for the drug nebulization studies and DBA/2 mice were used for the murine P. aeruginosa
pneumonia model (Wilson et al., 2007). Mice were housed in the Marshall University Animal
Facility under veterinary supervision. The age of mice tested were between 8 and 12 weeks. The
weight of each mouse was taken prior to testing. All mouse work was performed by B. Kirby.
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Drug Nebulization.
C57BL/6 mice (n=8) were first exposed to 5 mL of nebulized DMSO for 10 minutes to
determine any adverse effects that may occur from using DMSO. Mice (n=16) were then
exposed to TOB in 0.225% saline or RFX in DMSO via nebulization until the 5 mL drug mixture
was depleted – typically 10-15 minutes. Nebulization was conducted using the pressure-based
nebulizer and chamber purchased from Kent Scientific (Torrington, CT). TOB was nebulized at
concentrations of 100 mg (n=4) or 400 mg (n=4) in 5 mL of 0.225% saline. RFX was nebulized
at concentrations of 100 mg (n=4) or 400 mg (n=4) in 5 mL of 100% dimethyl sulfoxide. Mice
were sacrificed immediately after nebulization via CO2 chamber. Lungs were then collected and
homogenized. TOB concentrations were measured using ELISA. RFX concentrations were
measured via HPLC.
ELISA analysis of TOB tissue concentration.
TOB concentration in the lung tissue was measured via ELISA following the protocol
established by Sachetelli et al. (Sachetelli, Beaulac, & Lagace, 1998). Briefly, a 96-well flat
bottom micro-titer plate was coated with 0.1% alcian blue in 3% acetic acid and incubated for 30
min at 37 °C. The plates were then washed twice with PBS and dried at RT. After drying, the
plates were coated with TOB in carbonate buffer for generating the standard curve or with lung
homogenate samples overnight at RT. The plates were then washed twice with PBS containing
0.05% Tween 20 (PBS-T). Skim milk in PBS-T was then added to the wells and incubated
overnight at 37 °C. The plates were washed with PBS-T and sheep IgG anti-TOB polyclonal
antibody (Cat: PA175463; Thermo Scientific) was added and incubated 1 h at 37 °C. The plates
were then washed three times with PBS-T and HRP-conjugated rabbit anti-sheep IgG polyclonal
antibody (Thermo Scientific) was added and incubated 1 h at 37 °C. The plates were then washed
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three times with 0.05% PBS Tween 20 and TMB solution was added and incubated for 30
minutes at RT. Acid stop solution was added and absorbance was read on a SpectraMax
spectrophotometer at 450 nm and 540 nm. Concentrations of TOB in lung samples were
determined by reference to a standard curve generated with the known amount of HPLC grade
TOB.
HPLC analysis of RFX tissue concentration.
HPLC analysis of RFX in the lung homogenates was performed to determine the amount
of RFX retained in the mouse lungs using an adaptation of a previously-published method (R. N.
Rao, Vali, & Rao, 2012). Briefly we used a Beckman HPLC system gold or a Waters Alliance
HPLC system. The samples were centrifuged at 1000g for 10 min and the supernatant collected.
An aliquot of the supernatant was injected on a 5 micron Waters XTerra R18 Column (250
mmx4.6 mm). The mobile phase was a 45:55 mix of 0.1% acetic acid: acetonitrile with a flow
rate of 1 mL/min. The detector was a Beckman photodiode array at 239 nm. The amount of RFX
in lung samples was determined by reference to RFX standards analyzed by the same HPLC
method. HPLC work was performed in M. Valentovic’s laboratory.
Particle size analysis of aerosol drugs.
Samples of TOB in 0.225% saline and RFX in 100% DMSO at concentrations of 60
mg/mL for both were prepared and submitted along with nebulizer unit used for animal
experiments. A Malvern Spraytec was used for analysis with the tested product sprayed
horizontally at less than 5 cm from the detector beam. The samples were measured in triplicates
for 20-30 seconds of stable operation of the nebulizer. Refractive index and absorption values
used were that of DMSO for RFX and water for TOB. Droplet size analysis of drugs used for
aerosol therapy was conducted by Spray Analytics (Lincolnshire, IL) by K. Butz.
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Murine pneumonia model treatment.
TOB or RFX were used to treat P. aeruginosa respiratory infection in a DBA/2 mouse
model established by Yu et al. (Wilson et al., 2007). Lung infection was induced by a single
exposure to a total of 84 male DBA/2 mice of 8-week old (Charles River Laboratories) to P.
aeruginosa PAO1 aerosols, which was prepared as previously reported. Immediately after
infection, the mice were separated into seven groups (n=12 per group): 1) control with no
treatment, 2) treatment with 300 mg TOB immediately after infection, 3) treatment with 300 mg
RFX immediately after infection, 4) treatment with 300 mg TOB 6 h after infection, 5) treatment
with 300 mg RFX 6 h after infection, 6) treatment with 300 mg TOB 12 h after infection, or 7)
treatment with 300 mg RFX 12 h after infection. Each experimental group was treated with TOB
or RFX with a control group treated with PBS following the nebulization protocol as described
above. The mice were monitored for survival at 12-hour intervals for 72 hours and then at 24hour intervals for 6 weeks.
Multiple doses of TOB with or without RFX were used to treat a P. aeruginosa
respiratory infection in a DBA/2 mouse model established by Yu et al. (Wilson et al., 2007);
however, the PAO1 strain used had a bioluminescent operon (luxCDABE). Female DBA/2 mice
were infected at 0 hour and split into 3 experimental groups of 8: no treatment; treatment with
300 mg TOB at 6, 8, and 10 h post-infection; or treatment with 300 mg RFX at 6 h and 300 mg
TOB at 8 and 10 h post-infection. Two mice from each group were sacrificed at 12, 18, and 24 h
post-infection. Lungs from sacrificed mice were homogenized in 1% PPBS and tested for
bacterial growth to determine CFU load per mouse. Bacteria grown were also imaged for
evidence of bioluminescence. Two mice from each group were left to observe for survival.
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Statistical Analysis.
The one-way and two-way ANOVA, Kaplan-Meier plots and Mantel-Cox test were used
to analyze the data, with statistical significance set at p<0.01. All statistical analysis was
performed using GraphPad Prism version 7.02 for windows (GraphPad Software, La Jolla, CA).
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Abstract
Pneumonia is a complicating and pervasive lower respiratory tract infection (LRTI)
among community and hospital settings. Diagnosing and effectively treating the microbial
etiology of LRTIs remains challenging due to the limited sensitivity and specificity of
conventional culture-dependent diagnostics. In this study, we develop a rapid semi-quantitative
multiplex PCR (mPCR) to be used on DNA extracted directly from respiratory specimens. The
mPCR would aim at identifying target genes in specific pathogens. This culture-independent
method would aid in identifying the causative pathogen(s) of LRTIs and can even identify
selected resistance genes, such as methicillin resistance (mecA) in Staphylococcus aureus. The
mPCR was validated using a murine lung infection model, in which the etiological agent’s
identity and relative abundance determined by mPCR paralleled the results of metagenomic
sequencing at six different timepoints. Moreover, when tested on bronchoalveolar lavage
samples derived from intubated intensive care unit patients, mPCR identified infections semiquantitatively in the clinical samples at least 24 hours prior to conventional culture methods.
This method aims to reduce LRTI diagnosis times and produce results for pathogen-directed
antimicrobial therapy. Furthermore, this cost-effective method can be readily implemented in all
hospital diagnostic laboratories since it does not require specialized instruments nor training.
Introduction
Hospital-acquired pneumonia is a life-threatening condition to patients receiving medical
care, particularly those in the intensive care unit (ICU) or with compromised immunity. Nearly
half of all hospital-acquired pneumonia cases are linked to mechanical ventilation (Kalanuria,
Ziai, & Mirski, 2014). The diagnosis of and therapeutic approach to ventilator-associated
pneumonia (Schaber et al., 2004) relies heavily on culture-dependent methods; however, these
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tests are disadvantaged by the limited ability to culture fastidious microbes, lack of sensitivity,
and length of time required to obtain results (Koenig & Truwit, 2006). Early detection and
diagnosis of the causative agent of ventilator associated pneumonia (VAP) (Schaber et al., 2004)
is critical to positive patient prognoses and to prevent the misuse of antibiotics (Golia et al.,
2013).
For these reasons, molecular diagnostics have become a promising alternative to
conventional cultivation techniques, as they provide the means for not only detecting pathogens,
but also the microbial genes that confer virulence and antibiotic resistance from samples of low
biomass (Torres, Lee, Cilloniz, Vila, & Van der Eerden, 2016). Indeed, automated machines,
such as FilmArray Respiratory Panel® and Curetis Unyvero P50®, utilize multiplex polymerase
chain reaction (PCR) for the rapid diagnosis of respiratory pathogens; however, a gold standard
for the microbiological diagnosis of VAP ceases to exist. Thus, a rapid, yet practical molecular
diagnostic that can be universally implemented, including at small-scaled or rural medical
facilities, is urgently needed (Torres et al., 2016).
In this study, we aim to establish a multiplex PCR (mPCR) method that will aid in the
rapid identification of the common pathogens that cause VAP in patients in the ICU. Using this
technique, VAP microbiological testing can be performed in under 4 hours with basic laboratory
equipment and limited technical skill. We show that by applying mPCR to clinical samples, we
were able to correctly identify pathogens originating from samples of ventilated patients at the
onset of infection. These pathogens were detectable by mPCR prior to detection using
conventional culture methods. Using a murine lung infection model, we also validated this
method as a practical application to identify the causative agent of a lower respiratory tract
infection (LRTI) and semi-quantitate the pathogen’s abundance throughout the infection.
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Moreover, we show that in a polymicrobial community, Gram-positive and Gram-negative
pathogens are distinguished and accurately identified using this technique. We have also
included the mecA gene in the mPCR diagnostic panel, which is responsible for methicillin
resistance in Staphylococcus aureus—a bacterium that is problematic in hospital-acquired
infections, especially in cases of VAP.
Results
Method Development
Primers for testing (Table 10) were split into two mixtures, Gram-positive cocci (P) that
included the 16S rDNA primers and the primers for S. aureus and MRSA, and the Gramnegative rods (N) that included primers for A. baumannii, P. aeruginosa, and E. coli. The 16S
band was added to compare the other bacterial bands to in order to deduce a comparative
pathogenic load to the total bacterial load in the sample that could include normal oral flora
bacteria.
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Bacteria
16s rDNA
Acinetobacter baumannii

Escherichia coli
Methicillin Resistant
Staphylococcus aureus
Pseudomonas aeruginosa
Staphylococcus aureus

Gene
27F
1492R
sp4F
sp4R

Sequence
(5’-AGAGTTTGATCMTGGCTCAG-3’)
(5’-CGGTTACCTTGTTACGACTT-3’)
(5’-CACGCCGTAAGAGTGCATTA-3’)
(5’-AACGGAGCTTGTCAGGGTTA-3’)

lacZF
lacZR
mecAF
mecAR
mucEF
mucER
nucAF
nucAR

(5’-TTGAAAATGGTCTGCTGCTG-3’)
(5’-TATTGGCTTCATCCACCACA-3’)
(5’-GTAGAAATGACTGAACGTCCGATAA-3’)
(5’-CCAATTCCACATTGTTTCGGTCTAA-3’)
(5’-ACGGTGCACCGTCCAGGCCTGT-3’)
(5’-TCTTCAGATTCTTCCGCGCTATT-3’)
(5'-GCGATTGATGGTGATACGGTT-3')
(5'-AGCCAAGCCTTGACGAACTAAAGC-3')

Table 10. Primers used for PCR
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Band Size (bp)
1,500

Reference
This study

300

(Higgins,
Wisplinghoff,
Krut, &
Seifert, 2007)
(Edin et al.,
2015)
(Edin et al.,
2015)
(Edin et al.,
2015)
(Brakstad,
Aasbakk, &
Maeland,
1992)

1500
275
600
300

Annealing Temperatures of Primer Sets
To determine the optimal annealing temperatures of the primers used in this study, a PCR
gradient was performed with DNA extracted from each bacterial reference strain and their
respective primer set. The annealing temperature of each primer set was tested at the following
temperatures: 68 ° C, 66.9 ° C, 65 °C, 61.9 °C, 57.8 °C, 54.8 °C, 52.8 °C, 51.5 °C; with 57 °C
chosen as the optimal annealing temperature. Each PCR reaction contained 100 ng DNA
template.
Cycle Number, DNA Template Concentration, and Extension Times
Using the optimal annealing temperatures established above, DNA extracted from each
bacterial reference strain and their respective primer set was tested under various conditions of
input DNA, PCR cycle numbers, and extension times to optimize accurate replication of the
target DNA. For each bacterial reference strain and primer set, DNA template concentrations
were tested at 100, 75, 50, 25, and 10 ng under the conditions of 35, 38, and 40 PCR
amplification cycles. At 35 cycles the detection of low levels of DNA was limited, with 25 ng
DNA template being the lowest detectable amount. However, at 40 cycles, a high amount of
nonspecific binding and unintended bands were observed (data not shown). Using 38 cycles, the
nonspecific bands were eliminated, and the PCR products were detected at the minimum DNA
concentration of 10 ng. Two different extension times were also tested: 60 seconds and 90
seconds at 72 °C. At an extension time of 90 seconds, a number of nonspecific bands were
observed. These bands were eliminated when the extension time was reduced to 60 seconds.
Mixture Testing with Reference Strains
Mixtures of Gram-positive (S. aureus) and Gram-negative (P. aeruginosa) bacterial DNA
were tested to determine if the PCR method could identify both species correctly or whether the
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method would favor the amplification of one PCR product over another. Gram-positive and
Gram-negative DNA was mixed at the following ratios: 1:3, 1:1, and 3:1 (30:100 ng, 30:30 ng,
and 100:30 ng). In all six cases, PCR products for both S. aureus and P. aeruginosa were
detected, giving confidence that in the case of a polymicrobial infection i.e., an infection where
Gram-positive and Gram-negative pathogens are present, both species would be correctly
identified with the mPCR method.
Mouse Infection and Sequencing Data
As a proof of concept of this method, we induced a P. aeruginosa LRTI in DBA/2 mice
and performed a semi-quantitative analysis on the abundance of Pseudomonas in the lungs over
the course of the infection. The relative abundance of Pseudomonas detected by the developed
mPCR method was compared to the results of metagenomic sequencing. For this model, DBA/2
mice were inoculated with 5 x1010 CFU of P. aeruginosa via an aerosol chamber. At 0, 12, 24,
36, 48, 60 hours post-infection, mice were humanely sacrificed for the collection of their lungs,
which were subsequently homogenized. Bacterial genomic DNA was extracted from lung
homogenates, and the gDNA was subjected to analysis by mPCR as well as 16S rRNA
metagenomic sequencing for microbiome analysis.
Taxonomic analysis of the lung microbiota (Fig. 27) showed that Pseudomonas was the
dominant microbial feature at every timepoint. On average, approximately 54% of the features
(denoted as ‘unassigned’) in each sample mapped to Mus musculus DNA. Although host DNA
contamination can be removed bioinformatically, for the purpose of this study, we chose to
include it, as it likely reflects the characteristics and quality of bacterial DNA extracted from
clinical samples, especially at sites of low biomass such as the lung.

102

12 hour

0 hour
8.34e-004% Ambiguous Taxa
2.79% Other Genera
45.15% Pseudomonas
52.06% Unassigned

1.16e-003% Ambiguous Taxa
1.41% Other Genera
77.93% Pseudomonas
20.66% Unassigned

36 hour

24 hour
3.03e-003% Ambiguous Taxa
5.36% Other Genera
21.20% Pseudomonas
73.43% Unassigned

1.07e-003% Ambiguous Taxa
4.77% Other Genera
15.98% Pseudomonas
79.25% Unassigned

48 hour

60 hour
4.00e-004% Ambiguous Taxa
0.82% Other Genera
72.60% Pseudomonas
26.58% Unassigned

1.70e-003% Ambiguous Taxa
3.00% Other Genera
3.30% Pseudomonas
93.70% Unassigned

Figure 27. Taxonomic analysis of the Pseudomonas murine lung infection model.
Pie charts show the relative abundance of taxa present in the lungs of mice post-infection at 0 h,
12 h, 24 h, 36 h, 48 h, and 60 h. Pseudomonas was the main taxon present and its abundance
fluctuated over the course of infection.
Using a DNA sample representative of each timepoint of the lung infection, we compared
the relative abundance of Pseudomonas inferred through metagenomic sequencing to the relative
fluorescence intensity of the Pseudomonas PCR gel band produced using the mPCR method
(Fig. 28A). Our results show that both methods projected similar abundance patterns of
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Pseudomonas at each timepoint in the lung infection. Furthermore, we found a significant (p=
0.0042) linear relationship (Fig. 28 B) between Pseudomonas PCR band intensities and
Pseudomonas feature abundances based on metagenomic sequencing results. Together, these
results lend credence to the validity and sensitivity of this method to detect and semi-quantitate
the abundance of a pathogen from a heterogeneous DNA sample.

Figure 28. Validation of the multiplex PCR as a method to detect and semi-quantitate the
abundance of the causative agent in a murine lung infection model.
DBA/2 mice were infected with P. aeruginosa via an aerosol chamber. At 0, 12, 24, 36, 48, 60
hours post-infection, the lungs were collected for bacterial DNA extraction, which was subjected
to analysis by metagenomic sequencing and multiplex PCR. (A) Plot shows the mean intensity of
DNA bands from agarose gel measured from three mice in triplicates. Error bars represent ± SE.
(B) The relative abundance of Pseudomonas at different infection timepoints was determined
through metagenomic sequencing and was compared to the relative fluorescence intensity of the
Pseudomonas PCR band produced by the multiplex PCR method. Data points are representative
of the mean ± SD. (C) Scatter plot with 95% confidence intervals of the regression line for
Pseudomonas PCR band intensities and Pseudomonas feature abundance based on metagenomic
sequencing results.
Patient Samples
Using the optimal PCR conditions established in this study, clinical samples were tested
to validate the ability of the mPCR method to correctly and accurately identify the common
microbial etiologies of VAP. Samples were obtained from mechanically ventilated patients in the
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ICU at Cabell Huntington Hospital. To determine whether the samples harbored infectious
pathogens, the clinical specimens were inoculated onto Sheep Blood and MacConkey agar biplates for 24 h at 37 °C for in vitro cultivation.
Of the tested samples a total of 30 samples from 15 different patients showed pathogenic
bacterial growth on the bi-plates. Moreover, a random selection of negative samples that either
showed no growth on the plates after 24 h or growth resembling normal oral flora after 24 h were
used for testing. The gels for the tested samples are summarized in figures 29 and 30. Each
patient sample is represented by two lanes, marked as P and N lane for the Gram-positive cocci
tested and Gram-negative rods tested. (Table 11). The 16S band used to determine the relative
bacterial load is seen at the 1.5 kb level in the P lanes for the samples, while bands at 300 bp and
275 bp in the P lanes represent S. aureus and MRSA respectively, and bands at 300 bp, 600 bp,
and 1.5 kb in the N lanes respectively represent A. baumannii, P. aeruginosa, and E.coli in the
samples.
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Figure 29. Select Positive patient samples summary. Agarose gel of PCR products from
patient samples 1 through 16 that showed growth resembling pathogenic bacteria on the agar
plates. The lane for the Gram-positive primers mix is designated (P) and the lane for the Gramnegative primers mix is designated (N). Bands at the 1.5 kb size in the P lanes of each patient
sample represent the 16S rDNA used for quantification of the relative bacterial load in each
sample. Bands at 300 bp and 275 bp in the P lane represent S. aureus and MRSA respectively as
seen in patient sample 28, 29, 30. Bands at 600 bp in the N lane represent P. aeruginosa
infection as seen in sample 19 and 20. Bands at 300 bp in the N lane represent A. baumannii
infection as seen in sample 14 and 15. All other bands were deemed non-specific bands.
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10000 bp

1500 bp
1000 bp
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Figure 30. Select negative and normal flora patient samples summary. (left) Agarose gels of
PCR products from patient samples 31 through 38 that had no growth visible on the agar plates.
Patients 31, 33, 34 and 36 showed bands in the P lane representing the 16S rDNA band at 1.5 kb,
while all other bands were deemed to be non-specific bands that didn’t correlate with the target
genes tested. (right) Agarose gels of PCR products from patient samples 39 through 45 that
showed growth representing normal flora of the oral cavity on the agar plates. All tested samples,
except for patient 39 and 44, had a 16S rDNA band in the P lane at the 1.5 kb. Patients 39 and 44
had a band at 300 bp in the P lane that represented S. aureus, while all the other bands where
deemed non-specific to the target genes being tested for. The lane for the Gram-positive primers
mix is designated (P) and the lane for the Gram-negative primers mix is designated (N).
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Project ID Number

Patient ID Number

Day of Sampling

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45

13.1
20.1
20.9
20.12
21.1
23.1
23.2
23.3
32.1
32.3
32.9
33.1
33.2
34.1
34.2
34.3
40.2
40.3
57.1
57.2
59.2
64.1
96.1
109.1
109.9
129.1
129.6
140.1
140.2
140.3
12.1
22.1
52.1
53.1
72.1
80.2
91.9
94.9
58.6
75.2
79.1
79.3
79.6
80.3
87.3

1
1
9
12
1
1
2
3
1
3
9
1
2
1
2
3
2
3
1
2
2
1
1
1
9
1
6
1
2
3
1
1
1
1
1
2
9
9
6
2
1
3
6
3
3

Table 11. Patient Samples Labels Summary
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Three selected patients were chosen that showed growth on 3 different days of sampling.
Patient 20 (Fig. 31) showed growth on day 1 that was representative of S. aureus on Blood agar
plate and later showed a Gram-Negative (lactose non-fermenter) bacterial growth on the
MacConkey plates that increased in load between days 9 and 12. The pathogens, S. aureus and A.
baumannii, were detected when using the mPCR where a 16S band showed a heavy bacterial
load on Day 1 and a band for S. aureus. The levels of S. aureus load decreased, as shown by a
decrease in band intensity of the 300 bp bands in the P lanes, and the levels of A. baumannii
increased, due to the appearance of the 300 bp bands in the N lanes between Day 9 and 12.
Patient 34 (Fig. 32) had a high bacterial load on all 3 days with a Gram-Negative
signal/growth (lactose non-fermenter) on MacConkey agar. The gels showed similar results with
a 300 bp band seen in the N lane on all three days and a 16S band that mimicked the bacterial
load seen on the plates. S. aureus is seen in the mPCR on Day 2 but not on the plates. It is
possible the growth from the A. baumannii out-competed and masked the S. aureus growth on
the blood agar plates.
Patient 140 (Fig. 33) showed growth on Blood Agar plates with a high S. aureus count,
represented by the large amount of bacterial growth on the plate. The gels showed corresponding
results, with a thick band in the P lane at 300 bp and 275 bp, indicating both S. aureus and mecA
gene representing MRSA, respectively.
Some non-specific bands were observed in the mPCR which was expected considering
that the DNA was directly extracted from aspirates without any bacterial enrichment techniques.
This extraction method can result in a mixed sample containing DNA from all the present
microorganisms as well as host DNA, which can alter the quality of the extracted bacterial
genomic DNA. To confirm that the bands seen on the gels correspond to the target gene and not
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just a non-specific amplicon, samples selected at random could be sequenced for confirmation.
These results could help alleviate any suspicions about the true ability to target multiple genes in
a multiplex PCR setup from direct extracts of DNA from patient samples.

10000 bp

1500 bp
1000 bp

300 bp

Figure 31. Summary of Patient 20. Bronchoalveolar lavages (BAL) samples were collected
from patient #20 on days 1, 9, and 12 of intubation in the ICU. (A) Results of in vitro cultivation
of BAL samples grown on Blood and MacConkey agar bi-plates at 37 °C for 24 hours (B)
Agarose gel of patient #20’s BAL samples after analysis with multiplex PCR. Each timepoint
was analyzed over two lanes: the first lane is the Gram-positive primer mix (P) and the second is
the Gram-negative primer mix (N). The 16s rDNA bands at 1.5kb and the S. aureus and A.
baumannii bands at 300bp are highlighted.
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Figure 32. Summary of Patient 34. Bronchoalveolar lavages (BAL) samples were collected
from patient #34 on days 1, 2, and 3 of intubation in the ICU. (A) Results of in vitro cultivation
of BAL samples grown on Blood and MacConkey agar bi-plates at 37oC for 24 hours (B)
Agarose gel of patient #34’s BAL samples after analysis with multiplex PCR. Each timepoint
was analyzed over two lanes: the first lane is the Gram-positive primer mix (P) and the second is
the Gram-Negative primer mix (N). The 16s rDNA bands at 1.5kb and A. baumannii bands at
300bp are highlighted.
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Figure 33. Summary of Patient 140. Bronchoalveolar lavages (BAL) samples were collected
from patient #140 on days 1, 2, and 3 of intubation in the ICU. (A) Results of in vitro cultivation
of BAL samples grown on Blood and MacConkey agar bi-plates at 37oC for 24 hours (B)
Agarose gel of patient #140’s BAL samples after analysis with multiplex PCR. Each timepoint
was analyzed over two lanes: the first lane is the Gram-positive primer mix (P) and the second is
the Gram-negative primer mix (N). The 16s rDNA bands at 1.5kb and the S. aureus bands at
300bp are highlighted.

Discussion
The method developed in this paper is a semi-quantitative technique that uses the 16S
rDNA PCR band as a marker for the total bacterial burden in a sample and compares the amount
of the specific pathogen to it. This method would help estimate the bacterial load present in the
sample as part of the whole sampled biota. Given that the samples collected would contain
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amounts of bacteria that are present as normal flora in the oral cavity as well as the true
pathogen, our method would be able to identify the relative load of the infectious bacterial DNA
to that of the total mixed biota DNA.
The high sensitivity of this method enables the detection of a pathogen’s DNA in the
sample even when the bacterial load is too low to grow on agar plates, which is the conventional
diagnostic method. As shown with patient 20, A. baumannii DNA was detected in the sample
collected on day 1 of the patient’s intubation in the ICU; however, in vitro culture of the same
inoculum had no growth on the MacConkey plates. A. baumannii was detectable by mPCR on
day 1 yet on the other hand it was not detected by culture until days 9 and 12; meaning that
infections would be detected earlier in patients enabling a faster response and earlier treatment.
Moreover, since this method provides a daily snapshot of the bacterial burden, the burden of the
pathogen’s DNA can be monitored, and the treatment regimen evaluated based on the results
obtained using this PCR method. In samples 24 and 25 that corresponded to the same patient
(samples taken from day 1 and day 9) a latency of Pseudomonas DNA (amplicon of 600 bp) was
observed at day nine (sample 25) even though the plates showed no growth indicating the
presence of P. aeruginosa. This result means that using this method treatment of said patient’s
infection was proven inefficient and that Pseudomonas was still present in their lungs.
In several patients, pathogenic DNA was not observed until later in their hospital stay
which suggests that the infection they were treated for was a nosocomial infection rather than a
community acquired one. On the other hand, some patients had a minimal DNA load on the first
day of intubation that was not reflected in the growth plates and this infection later surfaced after
several days of intubation (Fig. 28). Based on the growth plates, such cases would have been
considered nosocomial infections yet using this PCR method you can see that this patient had a
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mild infection before being intubated that got exacerbated upon placing the patient on a
ventilator. This result means that this method can also aid as a quality control step to truly
identify nosocomial infections from community acquired infections in the intubated patients.
The advantage of using this PCR method, that uses genomic DNA directly extracted from
the sample, is the ability to bypass the culture plate’s step. Growth plates might introduce in vitro
selective pressure that might not represent the in vivo conditions in the lung. Different growth
conditions would allow for differential growth rates of the pathogens which might not be
reflective of the true abundance in the lung; therefore, using extracts directly from the sample
would eliminate this bias.
MRSA is a common pathogen in the ICU (Khan et al., 2018); therefore the ability to
target the mecA gene (gene responsible for methicillin resistance in S. aureus) would allow for a
better-targeted treatment regimen and help contain and control MRSA infection.
PCR methods to identify or detect viral infections are widely used for diagnosis;
therefore, adapting the PCR to diagnose bacterial-borne infections can be cost-effective, since
necessary instruments are already present in the diagnostic laboratory. Furthermore, the use of
PCR for diagnosis is more sensitive than traditional growth plates and would aid in identifying
infections earlier. Therefore, if implemented, this method could be used for early intervention for
LRTI resulting in more effective treatments. When complemented with traditional culturing
methods and serology methods, this high-speed PCR method could help produce more accurate
and reliable diagnosis.
Conclusion. This study has shown the ability to accurately identify and detect bacterial
infections in intubated patients. The use of the mPCR over the regular agar plate method for
diagnosis would be beneficial since it allows the early detection of infection as well as the ability
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to identify certain markers of antibiotic resistance, thereby aiding in the treatment decisions
taken. Moreover, our work showed that the use of mPCR has a higher sensitivity to bacterial
loads in the patient’s samples than regular culture methods.
Our future aim is to add more microbial strain-specific primers to this multiplex to allow
the detection of a larger, but more targeted group of causative agents. Moreover, the addition of
other resistance genes other than mecA would increase the impact of this diagnostic method and
add efficiency to the treatment of these infections. This multiplex can also be adapted to help
diagnose infections other than the VAP samples dealt with. This method is versatile and can
easily be used to quickly and accurately diagnose all bacterial infections.
Materials and Methods
Sample Collection and Handling
Patient selection for this study was based on the criterion that patients were mechanically
intubated in the ICU at Cabell Huntington Hospital at the time of specimen collection.
Bronchoalveolar lavages were aspirated from the intubated patients and collected in sterile
collection vials by a respiratory therapist. Samples were collected from December of 2015
through May of 2016. The samples were collected on days 1, 2, 3, 6, 9, and 12 of intubation,
when possible. A total of 261 samples were collected from 143 patients with 65 patients being
sampled only once and 78 patients being sampled two or more times. Vials were then transported
to the microbiology laboratory at Cabell Huntington Hospital and stored at 4 °C until collected.
Samples were transported on weekly basis from the microbiology laboratory to the research
laboratory at the Robert C. Byrd Biotechnology Science Center for processing and storage.
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Preliminary Sample Testing
Samples were recorded into an excel worksheet and inoculated onto Sheep Blood Agar/
MacConkey Agar Biplates (Remel, San Diego, CA) using a 10 µl disposable inoculation loop
(Fisherbrand, Pittsburgh, PA) and grown at 37 °C for 24 h. The remainder of the sample was
stored in 2 mL cryogenic vials (Corning Inc., Corning, NY) at -80 °C for subsequent DNA
extraction.
DNA Extraction
DNA from bronchioalveolar lavage samples was extracted using the Sputum Isolation
DNA kit (Norgen Biotek Corp., ON, Canada). 500 µl bronchioalveolar lavage sample was mixed
with 500 μL of Dithiothreitol 100 μg/mL (Fisher Scientific, Waltham, MA) to liquefy the
sputum. DNA was eluted into 100 μL of elution buffer.
DNA from of all six ATCC bacterial reference strains (Table 12) was extracted using the
DNeasy Blood and Tissue kit (Qiagen, Germantown, MD) using the protocols for Gram-positive
and Gram-negative bacteria.
Bacteria
Acinetobacter baumannii
Escherichia coli
Haemophilus influezae
Methicillin Resistant Staphylococcus aureus
Pseudomonas aeruginosa
Staphylococcus aureus

ATCC reference number
ATCC#19606
ATCC#8739
ATCC#49144
N315
ATCC#10145
ATCC#6538

Table 12. Bacteria strains used.
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Polymerase Chain Reaction
HotStarTaq Master Mix Kit (Qiagen, Germantown, MD) and Multiplex PCR Plus Kit
(Qiagen, Germantown, MD) were used for the PCR reactions. 25μL of the master mix was used,
in addition to 5μL of the primer mix containing forward and reverse primers each at 5µM
concentrations, 5μL of Q solution, and a volume of 15μL for DNA and RNase Free water,
resulting in a final volume 50μl. Primers used can be found in table 10.
PCR was run on the iCycler Thermal Cyclers (Bio-Rad) with the following settings: a
preheating step at 95 °C for 5 minutes used to activate the HotStarTaq DNA polymerase
followed by 38 cycles of 95 °C for 30 sec. for denaturing, 57 °C for 1 min. for annealing and 72
°C for 1 min. for extension. A final extension at 68 °C for 10 min. was used. Samples were then
run on a 1.5% agarose gel at 120V, for 75 minutes. Each DNA sample was PCR-amplified twice:
once with the gram-positive primer set and once with the Gram-negative primer set. The Grampositive set consisted of forward and reverse primers for the 16S rDNA gene, S. aureus, and
MRSA, while the gram-negative set consisted of primers for A. baumannii, E. coli, and P.
aeruginosa.
Mouse Infection Model
Mice.
Protocols for murine lung infection model were approved by Marshall University’s
Institutional Animal Care and Use Committee (IACUC). The DBA/2 mice used for the P.
aeruginosa pneumonia model (Wilson et al., 2007) were purchased from Charles River
Laboratories (Wilmington, MA), and subsequently housed in the Marshall University Animal
Facility under veterinary supervision. Mice were between the ages of 8-12 weeks at the time of
infection. All mouse infection work was done by B. Kirby.
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Murine pneumonia model and tissue collection.
Methods used to induced the P. aeruginosa aerosolized respiratory infection in the
DBA/2 mouse model were previously described by Wilson et al. (Wilson et al., 2007). Briefly,
18 male DBA/2 mice were exposed to P. aeruginosa PAO1 aerosol. Following humane
scarification, the lungs were harvested from three DBA/2 mice at 0, 12, 24, 36, 48, and 60 hours
post-infection. The lungs were collected aseptically from each mouse and stored at in 1 mL 1%
peptone PBS (PPBS) at -80 °C until DNA extraction.
Library Preparation and 16S rRNA Metagenomic Sequencing
The lungs were homogenized via bead beating and DNA was extracted using the
PowerFecal DNA kit (Qiagen, Germantown, MD) modified for tissue homogenate following
manufacturer’s recommendations. DNA purity and concentration were determined using Qubit
Fluorometry (Thermo Fisher Scientiﬁc, Waltham, MA, USA). Polyacrylamide gel
electrophoresis purified indexed primers (341F/518R) (Bartram, Lynch, Stearns, MorenoHagelsieb, & Neufeld, 2011) targeting the V3 region of the bacterial 16S rRNA gene were
obtained from Integrated DNA Technologies. AccuPrime Taq DNA Polymerase (Thermo Fisher
Scientiﬁc, 12346086) was used to amplify the V3 region, yielding an amplicon of approximately
320 base pairs (bp). Each PCR reaction contained a total of 60 ng genomic DNA, 0.5 l of 20
M forward primer, 0.5 l of 20 M reverse primer, 1 l AccuPrime PCR Master Mix with Taq
Polymerase, 5 l 10X AccuPrime Buffer II, and PCR-grade water for a total volume of 50 l.
PCR reactions were amplified on the MJ Research PTC-200 Peltier Thermal Cycler (Bio-Rad
Laboratories, Hercules, CA, USA) using the following conditions: 6 minute denaturation step at
95C; 30 cycles of 95C for 2 minutes, 50C for 2 minutes, and 72C for 2 minutes; 4 minute
extension step at 72C. Size and quality of the V3 libraries was assessed by electrophoresis on a
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2100 Bioanalyzer System (Agilent Technologies, Santa Clara, CA, USA). The pooled libraries
were sequenced in a 2x180 paired-end fashion in the rapid run mode on an Illumina HiSeq1500
with the addition of 15% PhiX to enhance sequencing quality and diversity. This work was done
by L. Blalock.
Lung Microbiota Analysis
Demultiplexed, paired-end sequences were imported into QIIME2 (Caporaso et al., 2010)
via the Casava 1.8 paired-end demultiplexed fastq format. Sequences were denoised using the
DADA2 plugin (Callahan et al., 2016). For microbial taxonomic analysis, operational taxonomic
units were assigned taxonomy with the QIIME2-formated version of SILVA_132_release (Quast
et al., 2013) at the sequence identity cutoff of 99%.
Statistical Analyses
Linear regression was performed in GraphPad Prism 8 (GraphPad Software, Inc.).
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CHAPTER 6
CONCLUSION AND FUTURE WORK

This dissertation aimed at understanding the link between pyrimidine biosynthesis and
alginate synthesis in P. aeruginosa. In addition, we also showed that the MucA mutant MucA22
can be degraded by all three known proteolytic enzymes AlgW, MucP, ClpXP. Furthermore, our
work aimed at repurposing the antimicrobial Rifaximin for use as a therapeutic agent for
treatment of chronic lung infections by P. aeruginosa. And finally, we showed that a multiplex
PCR method can be used as a rapid diagnostic tool for early detection of lower respiratory lung
infections that can aid in early intervention and treatment in patients with CF or VAP.
Linking SCV, Pyrimidine Biosynthesis and Alginate Production
Previously, there was no known link between the de novo pyrimidine biosynthetic
pathway and alginate synthesis. Several papers showed that disruption of pyrimidine
biosynthesis resulted in a change in biofilm production, or alteration of antimicrobial resistance
without fully identifying the link (Beaume et al., 2015; Ueda et al., 2009).
Upon disruption of pyrimidine biosynthesis through transposon insertion into the
Carbamoyl Phosphate Synthase/ Synthetase (carA, carB) and Dihydroorotate Dehydrogenase
(pyrD) genes the previously mucoid strain PAO581 (mucA25) become nonmucoid and had a
small colony variant phenotype when grown on PIA plates. Upon supplementation of the plate
with Uracil, the mucoid phenotype and normal colony morphology returned to PAO581.
Our work showed that the disruption of pyrimidine biosynthesis resulted in starvation of
the cell and slowed the DNA replication and transcription process as seen by low levels of
UMP/UTP. This disruption resulted in the observed SCV phenotype. In addition, the disruption
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of pyrimidine levels in the cell disrupted Nitrogen metabolism, since both pathways share
common metabolic products (Köhler et al., 1989; Shiau et al., 1992). This imbalance in nitrogen
metabolism resulted in the over-expression of the sigma factor RpoN, that is used by P.
aeruginosa to regulate nitrogen metabolism, in addition to various other pathways mainly
included in the acute virulence of P. aeruginosa (Potvin et al., 2008). Since RpoN and AlgU
have an overlapping binding region at the promoter region of the algD operon (alginate
biosynthetic operon) (Boucher et al., 1996) the two sigma factors compete for binding at that
site. With the overexpression of rpoN resulting in larger than normal concentrations of the sigma
factor in the cell, this competition for binding favored RpoN over AlgU due to basic
stoichiometry. Our work showed that AlgU levels remain equal regardless of pyrimidine
biosynthesis, yet the intracellular concentrations of RpoN fluctuated based on the availability of
intracellular pyrimidines (increased under low pyrimidine levels and returned to normal after
uracil supplementation). This work shows that this fluctuation in concentrations in pyrimidine is
the reason RpoN was able to out-compete AlgU for binding to a promoter region normally
occupied by AlgU. Upon addition of Uracil the RpoN levels returned to normal and the
advantage against AlgU was diminished.
These results show a great ability of the cell to regulate itself under stressful conditions,
such as pyrimidine starvation, through alteration of sigma factors availability and with it an
ability to modify its transcriptional activity. The fact that RpoN, a sigma that regulates acute
infection, has an overlapping binding region as AlgU, a regulator of the main component of
chronic infection state in P. aeruginosa, shows that this regulatory event exists in the cell to help
Pseudomonas adapt to its environment. Under stressed conditions, the bacteria can modify its
metabolic profile and through pathways like competing sigma factors can divert its metabolites
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towards more essential pathways needed for basic survival versus defensive pathways that might
be very energy expensive on the cell such as alginate production.
Sigma factor competition might be a key factor to understanding the switch of the
invading P. aeruginosa bacterial load from the highly virulent bacteria that initiate the infection
to the sessile, biofilm and mucoidy cells that are present later in the disease progression. To date,
the switch between planktonic to sessile has not yet been fully understood, even though work has
focused on transcriptional regulation of co-regulated pathways (Evans, 2015; Schniederjans et
al., 2017), it is possible that the answer lies in the sigma factor competition and intracellular
availability at the different times of infection, similar to what was observed in our work.
An interesting observation for Small Colony Variants (SCV), is that they have the ability
to switch between normal colony growth and SCV phenotype based on the environmental
pressures and the nutritional availability. Furthermore, some SCV do not arise from SNPs nor
from frame-shift mutations, but rather are a result of the alteration in transcriptional levels
(Schniederjans et al., 2017), or as seen in our work, as a result from necessary nutrient starvation.
When conditions are favorable the SCV phenotype is reversed and the normal colony
morphology is observed again. This phenomenon mimics sporulation in some bacteria such as
Bacillus, Clostridium and many other. Sporulation in these bacteria is a result of a harsh
environment where the bacteria becomes the dormant form -spore- until the conditions are
favorable again. Since SCV still continue to divide and grow unlike true spores, except their
growth is much slower compared to the normal colonies, therefore we can possibly name SCV a
Pseudo-Spore. The SCV change colony morphology as well as metabolic activity based on the
environmental conditions hence the spore-like comparison. Yet, unlike spores SCV still maintain
a growth rate even though it is slower and they cannot survive the extreme conditions that true
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spores can hence the “Pseudo” nomenclature. Therefore, it is fitting to name these special
colony variants as Pseudo-Spores.
Regulation of MucA22 Proteolysis
Our work showed that the mutant MucA22, one of the most common mutations of MucA
is degraded through a three-step process. The first enzyme to degrade MucA22 is AlgW that cuts
the periplasmic section (C-terminus) of MucA22 (D. Qiu et al., 2007). Then, MucP cuts the
inner-membrane section, and finally ClpXP cuts the cytoplasmic region (N-terminus) (D. Qiu, V.
Eisinger, N. Head, G. Pier, & H. Yu, 2008; Wood et al., 2006). Our work showed that disruption
of algW results in a higher cutting rate by MucP. When compared to the bands produced by
PAO1mucp and PAO1clpP/X, the expected bands were seen that show a deficiency in the
proteolytic cascade. Disruption of MucP resulted in two bands at 25 kDa and 16 kDa showing
that the intramembrane portion of MucA22 is not being cleaved which results in the
accumulation of the corresponding band (16 kDa). When ClpP and ClpX were disrupted the
cytoplasmic band was accumulating, as seen by a thicker 12 kDa than expected. Of the three
enzymes, disruption of AlgW is the only one with an anomalous result. Since previously it has
been difficult to clone MucA22, studying the proteolysis pattern of it was not fully understood.
Furthermore, the cleavage site for AlgW has been mapped and is known, yet the cleavage site for
MucP is not yet mapped. Equipped with this knowledge, we aim to further understand the
proteolysis of MucA22 and eventually map the cleavage sites of all enzymes on MucA22.
The importance of these findings is the ability to develop enzyme blockers for the RIP
proteases. Cleavage of MucA results in alginate production, and alginate is the main virulence
factor used by P. aeruginosa in the chronic infection. P. aeruginosa use the produced alginate
and biofilms for protection from its environment; therefore, blocking the cell’s ability to produce
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alginate would allow for better treatment efficiency and immune clearance of the infection.
Small molecules or enzyme blockers can be developed to block the binding sites of the enzymes,
where these small molecules would also be specific and thereby result in minimal side effects on
the patient’s body. These small molecules potentially could be used in addition to the used
antimicrobial regimen in order to enhance its efficacy as well as aid in their penetration ability of
the alginate.
Use of Rifaximin to Treat Chronic Lung Infections
In our work, we discovered Rifaximin, an antibiotic that is used orally for Traveler’s
Diarrhea and Hepatic Encephalopathy, to be effective on inhibiting the production of alginate in
Pseudomonas aeruginosa. Our work showed that Rifaximin was more effective on clinical
isolates than Tobramycin, the current gold standard for treating Cystic Fibrosis. Rifaximin
showed lower MIC levels when compared to Tobramycin and Amikacin. When compared to
Tobramycin, Rifaximin also had a higher capacity of blocking alginate production in both
reference strains as well as mucoid clinical isolates. Rifaximin showed that the inhibition of
alginate was a result of blocking the promoter activity of P algD (the promoter of the biosynthetic
operon for alginate). When combined with Tobramycin, Rifaximin showed synergy and was able
to aid in the inhibition of biofilm production. Tobramycin does not penetrate biofilms efficiently,
and with the aid of Rifaximin, and the ability to inhibit alginate production, Tobramycin can
penetrate the biofilms.
When tested on a murine mouse pneumonia model, Rifaximin showed promise in healing
symptoms associated with established pneumonia. When Rifaximin was supplemented to the
multiple dosing treatment of the mice, we observed a 100-fold reduction in the tested CFUs in
the lungs. The previous findings might suggest that in an established infection, possibly
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protected by biofilm, addition of Rifaximin as a treatment supplement increased the clearance of
the bacteria by Tobramycin. This work shows promise in Rifaximin and its ability to be a
supplement to Tobramycin for the treatment of chronic lung infections in Cystic Fibrosis
patients.
However, Rifaximin needs to be further investigated to fully understand the potential as a
therapeutic additive to Tobramycin, as well as a better understanding of the toxicity of Rifaximin
in the lung. Moreover, no true mouse model for chronic mucoid infection has been published.
The current mouse models used to study lung infections resemble acute infections where the
used strain is nonmucoid, and a true biofilm is never established in the lung. The use of a chronic
murine model would help study CF infections more accurately and help gauge the efficiency of
the currently used treatments on penetrating the preexisting mucoid plugs in the lungs to better
understand the capabilities of the drugs to penetrate the mucoid plug as well as the drug
bioavailability in the lung.
Lower Respiratory Tract Diagnostic PCR
We developed a multiplex PCR that could be used for the rapid diagnosis of lung
infections. Several targets on specific genes for S. aureus, Methicillin Resistant S. aureus
(MRSA), P. aeruginosa and other respiratory pathogens were used to design specific primers.
These primers were combined to make two sets of primer mixes that included the 16s rDNA
target as well as primers for S. aureus, and MRSA in the first set – Gram-positive Cocci (P)- and
primers for A. baumannii, E. coli, P. aeruginosa in the second- Gram-negative Rods (N).
To test the ability of the developed PCR, mice were infected with P. aeruginosa and their
lungs homogenized, and then DNA was extracted from the whole lung homogenate. The samples
were tested using both the PCR developed in this study and using metagenomic sequencing.
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When compared to each other both results showed the ability to identify P. aeruginosa in the
lungs, as well as the PCR gels managed to show the same trends seen in the deep sequencing
results. This work showed that the PCR can be used on true samples and is accurate in
identifying the pathogen.
Patient samples were collected from intubated patients at Cabell Huntington Hospital at
random over a 5-month period. These samples were tested using the traditional means of plate
culture growth onto Blood Agar plates and MacConkey Plates. DNA was then directly extracted
from the samples using a sputum DNA extraction kit. The extracted DNA was then used as a
proof of concept for the PCR. The results from the PCR corresponded with the growth observed
on the plates for the patients. At times the PCR was able to identify a pathogen before growth
was seen on the culture plates. This work showed that the use of the developed multiplex PCR
would result in accurate diagnosis for the samples and would allow faster results since the step of
culturing the sample on agar plates would be avoided. Similar testing procedures exist for upper
respiratory infections and for viral infections, but none exist for the lower respiratory tract;
therefore, this method would be beneficial for diagnostic laboratories. In addition, many kits that
are in use require a single colony isolate to be tested; therefore, the culturing step cannot be
avoided, whereas our developed method tests the sample directly and would be able to provide a
diagnosis in as little as 6 hours. Moreover, culturing samples on agar plates introduces a minor
bias where selective pressures that are not similar to the ones in-vivo exist. This bias thereby
would possibly allow certain strains to outgrow others and therefore not resemble the true
balance that existed in the sample. When DNA is extracted directly from the sample this bias,
though minute, would be eliminated and the true microbial diversity would be tested for.

126

Another advantage for this method is the ability of adapting a diagnostic laboratory to
perform it. The method requires a commercial DNA extraction kit, a thermal cycler – that is
usually available in all laboratories, and minimal levels of experience to perform it. Therefore,
the ease of use of the method and the low cost would make it a valuable candidate for diagnostic
laboratories that are either budget conscious or for smaller laboratories that would not be able to
afford specialized instruments for diagnosis nor specialized personnel.
For future development of the method, additional primer targets for common resistance
gene could be added similar to the mecA gene (the gene responsible for MRSA). With that
addition, treatment would be targeted and personalized for each patient. This development has
two distinct advantages. The first is limiting the use of broad-spectrum antibiotics that are used
early until a specific antibiotic can be chosen. The second has to do with MRSA. Since MRSA is
a very common nosocomial pathogen and since MRSA has a high incidence, the ability to
identify a Staphylococcus infection to be Methicillin resistant or not would help in the proper
treatment of these infections.
Future Work
Future work that relates to this dissertation will include mapping the complete
degradation pattern of MucA22. This work was started in Chapter 3, yet more work is needed to
fully understand how MucA22 results in a mucoid phenotype. In addition, it is important to
identify the cutting site of the protease MucP on both MucA and MucA22. Identifying the
cutting site would enable the development of small molecules that can work on blocking the
function of MucP and thereby inhibiting mucoidy in P. aeruginosa.
The work in Chapter 4 was merely a pilot study to identify the ability of RFX to inhibit
P. aeruginosa alginate production as well as to show that RFX can act synergistically with TOB
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to treat lung infections. Our future work would deal with further exploring the function of RFX
in the lungs as well as better characterizing RFX lung toxicity if any. Furthermore, we aim to
develop a way to use less toxic solvents for RFX, other than DMSO used, in order to eliminate
any lung toxicity that might arise from the use of DMSO. Determining a more suited regimen of
RFX and TOB combination treatments would help increase the efficiency of TOB treatments and
thereby save many CF patient’s lives, suffering from chronic P. aeruginosa lung infections.
The mPCR developed in Chapter 5 showed potential in being a rapid diagnostic tool that
is simple to implement in various conditions. The mPCR here was developed for diagnosis of
lung infections, yet it can easily be adapted for diagnosis of many other site-specific infections.
In addition, similar to the targeting of mecA, other known and problematic antimicrobial
resistance genes can be targeted to allow for better diagnosis and a more accurate treatment of
the infections. Since this process does not require much time to perform nor many specialized
instruments, it can also be adapted for field diagnosis in places where a rapid identification of
pathogens can save lives, such as in outbreaks, natural disasters, and also battlefields.
Finally, the CF immune response in the lungs is chronic in terms of time frame, yet the
nature and the immune cells present are those found in acute infections. The most common cells
in CF lung infections are neutrophils, where they play a major role in the immune response
against P. aeruginosa. In all other immune responses to bacterial invasions, neutrophils are short
lived and are present initially at the infection site but get replaced my monocytes and mast cells
when the infection switches from an acute short-term infection to a long-term chronic infection;
which is not the case in the CF lung. Therefore, a better definition for this infection would be a
persistent acute infection rather than the traditional nomenclature of chronic infection since this
infection is only chronic by time frame not by the immune response. Future work may focus on
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the reason behind the persistence of neutrophils in the lung and why the immune response never
switches to a true chronic response.
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APPENDIX B: LIST OF USED ABBREVIATIONS
°C
µg
µL
ANOVA
ANR
ASL
ASM
BAL
bp
CDC
CF
CFTR
CHH
ClCMP
COPD
CSO
CTP
Da
DMSO
DNA
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F
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FIC
g
h
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HCO3HPLC
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IACUC
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L
L
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LC-MS
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Degree Celsius
Microgram
Microliter
Analysis of Variance
Anaerobic Regulator
Airway Surface Liquid
American Society for Microbiology
Bronchoalveolar Lavage
Base Pairs
Center for Disease Control
Cystic Fibrosis
Cystic Fibrosis Transmembrane Conductance Regulator
Cabell Huntington Hospital
Chloride Ion
Cytidine Mono-Phosphate
Chronic Obstructive Pulmonary Disease
Chief Science Officer
Cytidine Tri-Phosphate
Daltons
Dimethylsulfoxide
Deoxyribonucleic Acid
Enzyme-Linked Immunosorbent Assay
Phenylalanine
Food and Drug Administration
Fractional Inhibition Concentration
Gram
Hour
Hemagglutinin
Bicarbonate
High Pressure Liquid Chromatography
Isoleucine
Institutional Animal Care and Use Committee
Intensive Care Unit
Institutional Review Board
Kilo Base Pairs
Kilo Daltons
Liter
Leucine
Lennox Broth
Liquid Chromatography- Mass Spectrometry
Lower Respiratory Tract
Lower Respiratory Tract Infection
Mucoid
Multi-Drug Resistant
150

mg
MIC
min
ml
mPCR
MRSA
MTT
Na+
ndk
ng
NIH
NM
OD
ONPG
PA
PBS
PCR
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PDZ
PIA
PIB
PK
PPBS
QS
RFX
RIP
RNA
SCFM2
SCV
SE
T3SS
TMB
TOB
UMP
URT
URTI
UTP
V
VAP
W
X-gal
Y
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Milligram
Minimal Inhibitory Concentration
Minutes
Milliliter
Multiplex Polymerase Chain Reaction
Methicillin Resistant S. aureus
Methyl thiazol tetrazolium
Sodium Ion
Nucleotide Diphosphate Kinase
Nanogram
National Institute of Health
Non-mucoid
Optical Density
ortho-Nitrophenyl-β-galactoside
Pseudomonas aeruginosa
Phosphate-Buffered Saline
Polymerase Chain Reaction
Protein Domain- Post synaptic density protein (PSD95),
Drosophila disc large tumor suppressor (Dlg1), and
Zonula occludens-1 protein (zo-1)
Pseudomonas Isolation Agar
Pseudomonas Isolation Broth
Pharmacokinetics
Peptone Phosphate-Buffered Saline
Quorum Sensing
Rifaximin
Regulated Intramembrane Proteolysis
Ribonucleic Acid
Synthetic Cystic Fibrosis Media 2
Small Colony Variant
Standard Error
Type 3 Secretion System
Tetramethylbenzidine
Tobramycin
Uridine Mono-Phosphate
Upper Respiratory Tract
Upper Respiratory Tract Infection
Uridine Tri-Phosphate
Valine
Ventilator Associated Pneumonia
Tryptophan
5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
Tyrosine
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